<SEC-DOCUMENT>0001144204-15-024658.txt : 20150423
<SEC-HEADER>0001144204-15-024658.hdr.sgml : 20150423
<ACCEPTANCE-DATETIME>20150423170413
ACCESSION NUMBER:		0001144204-15-024658
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20150423
DATE AS OF CHANGE:		20150423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ATOSSA GENETICS INC
		CENTRAL INDEX KEY:			0001488039
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				264753208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-192285
		FILM NUMBER:		15789198

	BUSINESS ADDRESS:	
		STREET 1:		2345 EASTLAKE AVENUE EAST
		STREET 2:		SUITE 201
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		206.588.0256

	MAIL ADDRESS:	
		STREET 1:		2345 EASTLAKE AVENUE EAST
		STREET 2:		SUITE 201
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>v408088_posam.htm
<DESCRIPTION>FORM POS AM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">As filed with the Securities
and Exchange Commission on April 23, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration Statement No. 333-192285</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POST-EFFECTIVE AMENDMENT NO. 2 TO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ATOSSA GENETICS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 33%; font-size: 10pt; text-align: center"><b>Delaware</b></td>
    <TD STYLE="width: 34%; font-size: 10pt; text-align: center"><b>3841</b></td>
    <TD STYLE="width: 33%; font-size: 10pt; text-align: center"><b>26-4753208</b></td></tr>
<tr style="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">organization)</P></td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Primary Standard</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Industrial Classification</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Code Number)</P></td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2345 Eastlake Ave. East, Suite 201</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Seattle, Washington 98102</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Telephone: (800) 351-3902</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address, including zip code, and telephone
number, including area code, of Registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Steven C. Quay</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Chairman, Chief Executive Officer and
President</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2345 Eastlake Ave. East, Suite 201</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Seattle, Washington 98102</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Telephone: (800) 351-3902</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, address, including zip code, and
telephone</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">number, including area code, of agent for
service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Copies to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Kyle Guse</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Financial Officer and General Counsel</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2345 Eastlake Ave. East, Suite 201</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Seattle, Washington 98102</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(800) 351-3902</P></td>
    <td style="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ryan A. Murr</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Gibson, Dunn &amp; Crutcher, LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">555 Mission Street, Suite 3000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Francisco, California 94105</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: (415) 398-8200</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Approximate date
of commencement of proposed sale to the public:</B> From time to time after this registration statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933 check the following box. <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form is filed
to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form is a
post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form is a
post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.25in">
<tr style="vertical-align: top">
    <TD STYLE="width: 32%; font-size: 10pt">Large accelerated filer</td>
    <TD STYLE="width: 36%; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></td>
    <TD STYLE="width: 29%; font-size: 10pt">Accelerated filer</td>
    <TD STYLE="width: 3%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></font></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt">Non-accelerated filer</td>
    <td style="font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></font></td>
    <td style="font-size: 10pt">Smaller reporting company</td>
    <td style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">(Do not check if a smaller
reporting company)</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant is an emerging growth company, as defined
in Section 2(a) of the Securities Act. This Registration Statement complies with the requirements that apply to an issuer that
is an emerging growth company. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The registrant hereby amends this Registration Statement
on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange
Commission, acting pursuant to said Section 8(a), may determine. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 100%">
<!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center">&nbsp;</td></tr>
</table>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Explanatory
Note:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On November 12, 2013, Atossa
Genetics Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;) filed a registration statement with the Securities and Exchange Commission
(the &ldquo;<B><I>Commission</I></B>&rdquo;) on Form S-1 (Registration No. 333-192285), which was amended on December 11, 2013
(as so amended, the &ldquo;<B><I>Registration Statement</I></B>&rdquo; or the &ldquo;<B><I>Form S-1</I></B>&rdquo;). The Registration
Statement was declared effective by the Commission on December 13, 2013 to register for resale by the selling stockholder identified
in the prospectus an aggregate of 4,200,000 shares of our Common Stock, $0.001 par value per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;).
On April 18, 2014 the Company filed a Post-Effective Amendment No. 1 to the Form S-1, which was declared effective by the Commission
on April 25, 2014. This Post-Effective Amendment No. 2 to the Form S-1 (the &ldquo;<B><I>Post-Effective Amendment No. 2</I></B>&rdquo;)
is being filed by the registrant pursuant to the undertakings in Item 17 of the Form S-1 to: (i) incorporate by reference the Company&rsquo;s
Annual Report on Form 10-K for the fiscal year ended December 31, 2014; and (ii) update certain other information in the Form S-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No additional securities are being registered
under this Post-Effective Amendment No. 2. All filing fees payable in connection with the registration of the shares of the Common
Stock covered by the Registration Statement were paid by the registrant at the time of the initial filing of the Form S-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 100%">
<!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>The information in this
prospectus is not complete and may be changed. The security holders identified in this prospectus may not sell these securities
until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer
to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not
permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preliminary Prospectus (Subject to
Completion)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>dated April 23, 2015 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="http:||www.sec.gov|Archives|edgar|data|1488039|000114420415022966|logo_atossagenetics-pms.jpg" STYLE="height: 99px; width: 263px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
<B>3,528,199 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus covers the sale of an aggregate
of up to 3,528,199<B> </B>shares of our common stock, $0.001 par value per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;),
by Aspire Capital Fund, LLC (&ldquo;<B><I>Aspire Capital</I></B>&rdquo; or the &ldquo;<B><I>Selling Stockholder</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The prices at which the Selling Stockholder
may sell the shares of Common Stock will be determined by the prevailing market price for the shares or in negotiated transactions.
We will not receive proceeds from the sale of the shares by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Stockholder is an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act of 1933, as amended. We will pay the expenses of registering these shares, but all selling
and other expenses incurred by the Selling Stockholder will be paid by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s Common Stock is traded
on the NASDAQ Capital Market under the symbol &ldquo;ATOS&rdquo;. On April 22, 2015, the closing sale price of our Common
Stock on the NASDAQ Capital Market was $1.65 per share. Our principal executive offices are located at 2345 Eastlake Ave.
East, Suite 201, Seattle, Washington 98102 and our telephone number is (800)&nbsp;351-3902.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Investing in our securities
involves risks. You should carefully consider the risk factors beginning on page 7 of this prospectus before you make an
investment in our securities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is , 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 94%"><A HREF="#s_015"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></td>
    <td style="vertical-align: bottom; width: 5%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_016"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PROSPECTUS SUMMARY</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_017"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS</FONT></A></td>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_018"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USE OF PROCEEDS</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_019"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DIVIDEND POLICY</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_020"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SELLING STOCKHOLDER</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_021"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">THE ASPIRE CAPITAL TRANSACTION</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_022"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_023"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF SECURITIES TO BE REGISTERED</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_024"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_025"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL MATTERS</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_026"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXPERTS</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_027"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></td></tr>
<TR STYLE="background-color: White">
    <td style="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><A HREF="#s_028"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></td>
    <td style="vertical-align: bottom; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You should read this prospectus, any applicable
prospectus supplement and the information incorporated by reference in this prospectus before making an investment in the securities
of Atossa Genetics Inc. See &ldquo;Where You Can Find Additional Information&rdquo; on page 11 for more information. You should
rely only on the information contained in or incorporated by reference in this prospectus or a prospectus supplement. The Company
has not authorized anyone to provide you with different information. This document may be used only in jurisdictions where offers
and sales of these securities are permitted. You should assume that information contained in this prospectus, or in any document
incorporated by reference, is accurate only as of any date on the front cover of the applicable document. Our business, financial
condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_015"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus and the documents incorporated
by reference into it contain, in addition to historical information, certain information, assumptions and discussions that may
constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;<B><I>Securities
Act</I></B>&rdquo;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;).
We have made these statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
These statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those
projected or anticipated. Although we believe our assumptions underlying our forward-looking statements are reasonable as of the
date of this prospectus, we cannot assure you that the forward-looking statements set out in this prospectus will prove to be accurate.
We typically identify these forward-looking statements by the use of forward-looking words such as &ldquo;expect,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo;
&ldquo;seek,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate&rdquo; or the negative
version of those words or other comparable words. Forward-looking statements contained in this prospectus include, but are not
limited to, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">Whether we maintain our clearances from the U.S. Food and Drug Administration, or FDA, and foreign regulatory bodies, and the CE Certificates of Conformity granted by our notified body, to sell, market and distribute our medical devices;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">whether we can achieve our revenue forecast and other financial projections for 2015;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to successfully launch and commercialize the FullCYTE Breast Aspirator in the United States and our ForeCYTE Breast Aspirator outside the United States;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to successfully continue selling and servicing Pharmacogenomics and NAF cytology testing in our laboratory;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to successfully sell our products and services at currently expected prices or otherwise at prices acceptable to us;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to successfully develop and commercialize new tests, tools and treatments currently in development and in the time frames currently expected;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to maintain our business relationships, including with our distributors, suppliers and customers, while we launch and commercialize the FullCYTE Breast Aspirator in the United States and ForeCYTE Breast Aspirator and laboratory tests outside the United States;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to engage third party suppliers to manufacture the ForeCYTE Breast Aspirator, FullCYTE Breast Aspirator, FullCYTE Microcatheter, other devices under development and their components at quantities and costs acceptable to us;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to satisfy ongoing FDA, European Union (EU) and foreign requirements for manufacturing, distributing, and promoting the FullCYTE Breast Aspirator, NAF cytology test and FullCYTE Microcatheter and to obtain regulatory approvals, clearances and CE Certificate of Conformity for our other products and services in development;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to successfully defend ongoing litigation, including the securities class action law suit filed against us on October 10, 2013, and other similar complaints that may be brought in the future, in a timely manner and within the coverage, scope and limits of our insurance policies;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">the benefits and clinical accuracy of our laboratory tests, including the NAF cytology and Pharmacogenomics tests;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to establish and maintain intellectual property rights covering our products and services;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">the willingness of health insurance companies, including those who are members of the MultiPlan, FedMed and HealthSmart networks, and other third party payors to approve our products and services for coverage and reimbursement;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to establish and maintain an independent sales representative force, including with our current and future distributors and their sub-distributors, to market our current products and services and those that we may develop;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our expectations regarding, and our ability to satisfy, federal, state and foreign regulatory requirements;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">the accuracy of our estimates of the size and characteristics of the markets that our products and services may address;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our expectations as to future financial performance, expense levels and liquidity sources;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to attract and retain key personnel; and</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%">&bull;</td>
    <td style="width: 90%">our ability to sell additional shares of our common stock to Aspire Capital under the terms of our purchase agreement with them.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus also contains estimates
and other statistical data provided by independent parties and by us relating to market size and growth and other industry data.
These and other forward-looking statements made in this prospectus are presented as of the date on which the statements are made.
We have included important factors in the cautionary statements included in this prospectus, particularly in the section titled
&ldquo;Risk Factors,&rdquo; that we believe could cause actual results or events to differ materially from the forward-looking
statements that we make. Our forward-looking statements do not reflect the potential impact of any new information, future events
or circumstances that may affect our business after the date of this prospectus. Except as required by law, we do not intend to
update any forward-looking statements after the date on which the statement is made, whether as a result of new information, future
events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_016"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>This summary highlights some information
from this prospectus. It may not contain all the information important to making an investment decision. You should read the following
summary together with the more detailed information regarding our Company and the securities being sold in this offering, including
&ldquo;Risk Factors&rdquo; and other information incorporated by reference herein. Unless otherwise noted, (1) the term &ldquo;Atossa
Genetics&rdquo; refers to Atossa Genetics Inc., a Delaware corporation, (2) the terms &ldquo;Atossa,&rdquo; the &ldquo;Company,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our,&rdquo; refer to the ongoing business operations of Atossa and its wholly-owned
subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), whether conducted through Atossa Genetics or
the NRLBH, although such references as they relate to our laboratory tests and services generally refer to the NRLBH, and (3) the
term &ldquo;Common Stock&rdquo; refers to shares of Atossa Genetics Inc.&rsquo;s Common Stock and the term &ldquo;stockholder(s)&rdquo;
refers to the holders of Common Stock or securities exercisable for Common Stock. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a healthcare company focused on
improving breast health through the development of a suite of laboratory services, medical devices and therapeutics. Our laboratory
services are being developed and performed by our wholly owned subsidiary, The National Reference Laboratory for Breast Health,
Inc. (the &ldquo;NRLBH&rdquo;). The NRLBH has developed and is currently marketing nipple aspirate fluid, or NAF, cytology tests
and pharmacogenomics tests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our medical devices include the ForeCYTE
Breast Aspirator for distribution outside the United States and the FullCYTE Breast Aspirator for the U.S. market. These devices
are intended for the collection of NAF for cytological testing at a laboratory. The current version of the ForeCYTE Breast Aspirator
is not cleared by the FDA for marketing in the United States; however, this device is CE-marked and is therefore being commercialized
in the European Union and the countries of the European Free Trade Association (EFTA). The FullCYTE Breast Aspirator does not have
a CE-mark, but it has been cleared by the FDA for the collection of NAF for cytological purposes. For this reason the FullCYTE
device is being commercialized for the U.S. market. Other devices under development include intraductal microcatheters for the
collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, and various tools for potential
use by breast surgeons. In March 2015, we launched the FullCYTE Breast Aspirator in the United States and the ForeCYTE Breast Aspirator
in the EU and the countries of the EFTA, initially focusing on the Netherlands, Germany, Switzerland, and the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The ForeCYTE Breast Aspirator will not
be launched in the United States unless and until we receive additional regulatory clearance from the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We plan to develop certain of our medical
devices and laboratory tests so that they can be used as companions to pharmaceutical therapies that we plan to develop. For example,
we plan to develop our patented intraductal microcatheters for the potential delivery of a pharmaceutical targeted to a condition
called ductal carcinoma in-situ, or DCIS, which is the most common type of non-invasive breast cancer. We also plan to develop
our medical devices and laboratory tests as companion diagnostics to pharmaceutical therapies to treat women at high risk of breast
cancer and for the treatment of ductal hyperplasia or proliferative epithelial disease (PED). These programs are in the early pre-clinical
stage and will require testing and approval and/or clearance from the FDA prior to commercialization in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our 2015 objectives consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><U>(1) Launch and commercialize the FullCYTE
Breast Aspirator in the United States</U>: We began the launch of our FullCYTE Breast Aspirator in the United States in March 2015.
We have engaged Thermo Fisher Scientific and Henry Schein Medical as our initial U.S. distributors and we plan to build our own
specialty sales force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><U>(2) Launch and commercialize the ForeCYTE
Breast Aspirator in the EU</U>: We received CE Certificate of Conformity from our notified body for the ForeCYTE Breast Aspirator
and Collection Kits in October 2014 and in March 2015 began the launch of this device in the EU and the countries of the European
Free Trade Association (EFTA), focusing initially on the Netherlands, Germany, Switzerland, and the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><U>(3) Maximize total gross revenue from
our products and services</U>: We plan to grow our revenue by selling our products and promoting the tests currently being offered
by the NRLBH, including NAF cytology tests and pharmacogenomics tests, and by developing and commercializing additional laboratory
tests. We launched the pharmacogenomics test in October 2014 and processed and reported 527 tests through December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><U>(4) Begin one or more clinical studies
using our devices and potential pharmaceutical therapy</U>: We plan to develop a pharmaceutical to be delivered through our patented
microcatheters, initially to treat DCIS. We also plan to develop a pharmaceutical to treat one or more conditions detected by the
laboratory tests conducted on the NAF specimens collected with our breast aspirator devices. In this fashion, our devices and laboratory
tests can be used as companion diagnostics to the therapies we plan to develop. We expect that these therapies and companion diagnostics
will initially target DCIS, ductal hyperplasia, PED and/or high risk women and will require lengthy and costly clinical trials
that we will undertake only with input and direction from the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Many of our medical devices and the NRLBH&rsquo;s
laboratory services, as well as the breast health companion diagnostics, are currently under development and, if required by the
FDA, we must receive additional regulatory clearances and/or approvals prior to marketing and commercialization. The current regulatory
status of our devices and the laboratory tests offered by the NRLBH is indicated in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The NRLBH has been certified pursuant to
the Clinical Laboratory Improvement Amendments, or CLIA. CLIA certification is legally required to receive reimbursement from federal
or state medical benefit programs, like Medicare and Medicaid, and is a practical requirement for most third-party insurance benefit
programs. Our CLIA-certified laboratory, which is permitted to accept samples from all 50 states under its CLIA certification,
its state licenses, or, in New York under recognized exemption provisions while its license application is pending, examines the
NAF specimens by cytological analysis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary of Our Products and Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our products and services currently being
offered and currently under development consist primarily of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid; vertical-align: top">Product or Service</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid; vertical-align: top">Regulatory Status</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid; vertical-align: top">Primary Market</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 1pt solid; vertical-align: top">Commercialization Status</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 19%; font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top">Laboratory Tests Offered or Being Developed by NRLBH</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 19%; font-size: 10pt; text-align: left; vertical-align: top">Pharmacogenomics Test</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 18%; font-size: 10pt; text-align: left; vertical-align: top">Laboratory Developed Test (LDT); not FDA approved or cleared</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 18%; font-size: 10pt; text-align: left; vertical-align: top">United States</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 18%; font-size: 10pt; text-align: left; vertical-align: top">Launched October 2014</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">NAF Cytology Test</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">LDT</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">United States</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Launched December 2012</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">NextCYTE Breast Cancer Test</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">LDT</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">United States</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Validation Stage</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">ArgusCYTE Breast Health Test</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">LDT</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">United States</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Validation Stage</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Other Tests</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Under Development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Various</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">N/A</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-indent: 0.5in; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-indent: 0.5in; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-indent: 0.5in; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-indent: 0.5in; text-align: left; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; text-align: left; vertical-align: top; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; text-align: left; vertical-align: top; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; text-align: left; vertical-align: top; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; text-align: left; vertical-align: top; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Medical Devices</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">FullCYTE Breast Aspirator</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">FDA Cleared</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">United States</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Launched March 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">ForeCYTE Breast Aspirator</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">CE Marked</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">EU and countries of EFTA</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Launched March 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">FullCYTE Microcatheter to Collect Ductal Lavage Fluid for Cytology and/or Deliver Therapeutics</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Additional FDA Clearance to be Sought</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">United States</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Validation Stage</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Various Diagnostic Tools Including Microendoscopes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">FDA Cleared; Additional Clearances may be Required</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">United States</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Pre-launch; Evaluating Commercial Opportunities</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; text-align: left; vertical-align: top; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; text-align: left; vertical-align: top; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; text-align: left; vertical-align: top; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.5in; text-align: left; vertical-align: top; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; vertical-align: top">Pharmaceuticals</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Therapeutic to treat ductal hyperplasia, PED or high risk women</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Pre-Clinical; Not approved by the FDA or any other foreign competent authorities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">United States; Europe</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Pre-clinical</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: 0.5in">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Therapeutic delivered via our microcatheter to treat DCIS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Pre-Clinical; Not approved by the FDA or any other foreign competent authorities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">United States; Europe</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">Pre-clinical</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have not yet established an ongoing
source of revenue sufficient to cover our operating costs and allow us to continue as a going concern. Our ability to continue
as a going concern is dependent on obtaining adequate capital to fund operating losses until we become profitable. We plan to obtain
additional capital resources by: selling our equity securities; selling the FullCYTE Breast Aspirator in the United States and
the ForeCYTE Breast Aspirator outside the United States; generating laboratory service revenue from our services performed by the
NRLBH; and borrowing from stockholders or others when needed. However, we cannot assure you that we will be successful in accomplishing
any of these plans and, if we are unable to obtain adequate capital, we could be forced to cease operations. In 2013, substantially
all of our revenue was from sales of the MASCT System and patient collection kits and from NAF cytology testing services performed
by the NRLBH and substantially all of our revenue in 2014 was from pharmacogenomics testing performed by the NRLBH. As a result
of the recall of the MASCT System and patient collection kits in October 2013, we did not generate revenue from October 2013 through
the third quarter of 2014 when we launched and began generating revenue from the pharmacogenomics test offered by the NRLBH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will incur additional sales and marketing
expenses as we commercialize the FullCYTE Breast Aspirator in the United States and the ForeCYTE Breast Aspirator in the EU and
EFTA and as we continue to promote our pharmacogenomics test. We will need to revise our sales and marketing materials, continue
hiring direct sales employees and engage new distributors. We also expect to continue to hire clinical consultants to assist in
the sales of our NAF cytology tests. The FullCYTE Breast Aspirator may not gain adoption as quickly as the ForeCYTE Breast Aspirator
and it may sell at lower margins. If so, our potential sales and revenues will be negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of being an Emerging Growth
Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a company with less than $1 billion
in revenue during our last fiscal year, we qualify as an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our
Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure
and other requirements that are otherwise applicable generally to public companies. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot; </font></td>
    <td style="width: 94%">only two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; disclosure;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot; </font></td>
    <td style="width: 94%">reduced disclosure about our executive compensation arrangements;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot; </font></td>
    <td style="width: 94%">not having to obtain non-binding advisory votes on executive compensation or golden parachute arrangements; and</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot; </font></td>
    <td style="width: 94%">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may take advantage of these exemptions
for up to five years from our initial public offering or such earlier time that we are no longer an emerging growth company. We
would cease to be an emerging growth company if we have more than $1 billion in annual revenue, we have more than $700 million
in market value of our stock held by non-affiliates, or we issue more than $1 billion of non-convertible debt over a three-year
period. We may choose to take advantage of some but not all of these reduced burdens. We have taken advantage of these reduced
reporting burdens in this prospectus, and the information that we provide may be different than what you might get from other public
companies in which you hold stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We were incorporated in Delaware in April
2009. Our principal executive offices are located at 2345 Eastlake Ave. East, Suite 201, Seattle, Washington 98102 and our telephone
number is (800) 351-3902. Our corporate website is located at <I>www.atossagenetics.com</I> and our laboratory website is located
at <I>www.nrlbh.com</I>. Information contained on, or that can be accessed through, our websites is not a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">MASCT is our registered trademark and Oxy-MASCT
and our name and logo are our trademarks. ForeCYTE, FullCYTE, NextCYTE, ForeCYTE Breast Aspirator and ArgusCYTE are our service
marks. This prospectus also includes additional trademarks, trade names and service marks of third parties, which are the property
of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 19%"><b>Common stock covered by this Prospectus: </b></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 80%">Up to 3,528,199 shares of Common Stock that may be offered and sold by Aspire Capital.</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common stock outstanding as of </b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>March 31, 2015: </b></P></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">27,217,257 shares, including shares previously issued to Aspire Capital.</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><b>Use of proceeds:</b></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">Aspire Capital will receive all of the proceeds from the sale of the shares offered for sale by it under this prospectus. We will not receive proceeds from the sale of the shares by Aspire Capital.</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><b>Risk factors: </b></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">The shares offered hereby involve a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 7.</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><b>Dividend policy:</b></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">We currently intend to retain any future earnings to fund the development and growth of our business. Therefore, we do not currently anticipate paying cash dividends on our Common Stock.</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><b>Trading Symbol:</b></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">Our Common Stock currently trades on the NASDAQ Capital Market under the symbol &ldquo;ATOS&rdquo;.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Common Stock Purchase Agreements
with Aspire Capital Fund, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On March 27, 2013 we entered into a stock
purchase agreement with Aspire Capital Fund, LLC, and pursuant to that agreement we have sold Common Stock to Aspire with aggregate
gross proceeds to us of approximately $11.3 million. On November 8, 2013 we terminated that agreement and entered into a new stock
purchase agreement with Aspire Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The November 8, 2013 stock purchase agreement
with Aspire Capital (the &ldquo;<B><I>Purchase Agreement</I></B>&rdquo;) provides that, upon the terms and subject to the conditions
and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $25 million of shares of our
Common Stock (this amount is in addition to the proceeds we received from sales to Aspire Capital under the March 27, 2013 agreement
with them) over the 30-month term of the agreement. Certain terms and conditions of the Purchase Agreement are described below.
In connection with our January 2014 public offering we agreed not to utilize the financing arrangement with Aspire for 120 days
following completion of that offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Concurrent with entering into the Purchase
Agreement, we also entered into a registration rights agreement with Aspire Capital. The registration rights agreement provides
that the Company will file one or more registration statements, as necessary, to register under the Securities Act the sale of
the shares of Common Stock that have been and may be issued to Aspire Capital under the Purchase Agreement. The Company agreed
to file an initial registration statement registering the sale of the shares by Aspire Capital with the SEC within 10 days of entering
into the Purchase Agreement. We further agreed to keep the registration statement effective and to indemnify Aspire Capital for
liabilities in connection with the sale of the shares under the terms of the registration rights agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of the date of this prospectus, we have
issued and sold a total of 3,528,199 shares to Aspire under the Purchase Agreement and may not issue any more shares thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The issuance of the all shares to Aspire
Capital under the Purchase Agreement is exempt from registration under the Securities Act, pursuant to the exemption for transactions
by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_017"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A purchase of our shares of Common Stock
is an investment in our securities and involves a high degree of risk. You should carefully consider the risks and uncertainties
and all other information contained in or incorporated by reference in this prospectus, including the risks and uncertainties discussed
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014. All of these risk factors are incorporated by reference
herein in their entirety. If any of these risks actually occur, our business, financial condition and results of operations would
likely suffer. In that case, the market price of the Common Stock could decline, and you may lose part or all of your investment
in our company. Additional risks of which we are not presently aware or that we currently believe are immaterial may also harm
our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_018"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Stockholder will receive all
of the proceeds from the sale of the shares offered for sale by it under this prospectus. We will not receive proceeds from the
sale of the shares by the Selling Stockholder. We will bear all reasonable expenses incident to the registration of the shares
under federal and state securities laws other than expenses incident to the delivery of the shares to be sold by the Selling Stockholder.
Any transfer taxes payable on these shares and any commissions and discounts payable to underwriters, agents, brokers or dealers
will be paid by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_019"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have not declared any dividends and
do not anticipate that we will declare dividends in the foreseeable future; rather, we intend to retain any future earnings for
the development of the business. Payment of future cash dividends, if any, will be at the discretion of our Board of Directors
after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs,
outstanding indebtedness and plans for expansion and restrictions imposed by lenders, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_020"></A>SELLING STOCKHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have included in this prospectus 3,528,199
shares of Common Stock issued to the Selling Stockholder pursuant to the Purchase Agreement, which represents the maximum number
of shares that may be sold hereunder by the Selling Stockholder. The following table sets forth certain information regarding the
Selling Stockholder and the shares of Common Stock beneficially owned by it as of March 31, 2015. The Selling Stockholder may offer
shares under this prospectus from time to time and may elect to sell none, some or all of the shares set forth below. As a result,
we cannot estimate the number of shares of Common Stock that the Selling Stockholder will beneficially own after termination of
sales under this prospectus. However, for the purposes of the table below, we have assumed that the Selling Stockholder will sell
all shares covered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Selling Stockholder</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares <BR> Beneficially <BR> Owned Before <BR> Offering (1)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of <BR> Outstanding Shares <BR> Beneficially Owned <BR> Before Offering</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares to be <BR> Sold in the <BR> Offering</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares <BR> Beneficially <BR> Owned After <BR> Offering</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of <BR> Outstanding <BR> Shares <BR> Beneficially <BR> Owned After <BR> Offering</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font-size: 10pt; text-align: left; padding-left: 1pt">Aspire Capital Fund, LLC (2)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,350,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4.9</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,528,199</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 3%">(1)</td>
    <td style="width: 96%">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In general, a person is deemed to be the beneficial owner of: (i) any shares of our Common Stock over which such person has sole or shared voting power or investment power, plus (ii) any shares which such person has the right to acquire beneficial ownership of within 60 days, whether through the exercise of options, warrants or otherwise. The percentage of ownership set forth above assumes the sale by the Company to Aspire Capital of all shares being offered pursuant to this prospectus and is based on 27,217,257 shares of our Common Stock outstanding as of March 31, 2015, which includes the 3,528,199 shares issued through that date to Aspire Capital.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 3%">(2)</td>
    <td style="width: 96%">Steven G. Martin, Erik J. Brown and Christos Komissopoulos, who are the principals of Aspire Capital, are deemed to be beneficial owners of all of the shares of Common Stock owned by Aspire Capital. Although Messrs. Martin, Brown and Komissopoulos are deemed to have shared voting and investment power over the shares being offered under the prospectus filed with the SEC in connection with the transactions contemplated under the Purchase Agreement, each disclaims beneficial ownership of these shares except to the extent of their pecuniary interest therein. Aspire Capital is not a licensed broker dealer or an affiliate of a licensed broker dealer.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: -0.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_021"></A>THE ASPIRE CAPITAL TRANSACTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On November 8, 2013, we entered into the
Purchase Agreement, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire
Capital was committed to purchase up to an aggregate of $25 million of shares of our Common Stock over the 30-month term of the
Purchase Agreement, subject to certain NASDAQ Capital Market limits described below. In consideration for entering into the Purchase
Agreement, concurrently with the execution of the Purchase Agreement we issued to Aspire Capital 375,000 shares of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Concurrent with entering into the Purchase
Agreement, we also entered into a registration rights agreement with Aspire Capital. The registration rights agreement provides
that the Company will file one or more registration statements, as necessary, to register under the Securities Act the sale of
the shares of Common Stock that have been and may be issued to Aspire Capital under the Purchase Agreement. The Company agreed
to file an initial registration statement registering the sale of the shares by Aspire Capital with the SEC within 10 days of entering
into the Purchase Agreement. We further agreed to keep the registration statement effective and to indemnify Aspire Capital for
liabilities in connection with the sale of the shares under the terms of the registration rights agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of the date of this prospectus, we have
issued and sold a total of 3,528,199 shares to Aspire under the Purchase Agreement and may not issue any more shares thereunder.
&nbsp;Pursuant to the Purchase Agreement and the Registration Rights Agreement, we are registering under the Securities Act these
3,528,199 shares of Common Stock issued to Aspire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compliance with the NASDAQ Capital Market Rules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Purchase Agreement provides that the
number of shares that may be sold pursuant to the Purchase Agreement is limited to 3,528,199, or the Exchange Cap, which represented
19.99% of our outstanding shares as of November 8, 2013. In order to remain compliant with the applicable listing maintenance rules
of the NASDAQ Capital Market, we would need to obtain shareholder approval or rely upon an exception pursuant to the rules of the
NASDAQ Capital Market in order to issue more than 19.99%. This limitation would not have applied if, at any time the Exchange Cap
was reached and at all times thereafter, the average price paid for all shares issued and sold under the Purchase Agreement were
equal to or greater than $1.98, which was the closing sale price of our Common Stock on November 7, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No Short-Selling or Hedging by Aspire Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Aspire Capital has agreed that neither
it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging, which
establishes a net short position with respect to our Common Stock during any time prior to the termination of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effect of Performance of the Purchase Agreement on Our Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Purchase Agreement does not limit the
ability of Aspire Capital to sell any or all of the shares registered in this offering. The sale by Aspire Capital of a significant
amount of shares registered in this offering at any given time could cause the market price of our Common Stock to decline or to
be highly volatile. Sales to Aspire Capital by us pursuant to the Purchase Agreement also may result in dilution to the interests
of other holders of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_022"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The shares may be sold or distributed from
time to time by the Selling Stockholder directly to one or more purchasers or through brokers, dealers, or underwriters who may
act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated
prices, or at fixed prices, which may be changed. The sale of the shares offered by this prospectus may be effected in one or more
of the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">ordinary brokers&rsquo; transactions;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">transactions involving cross or block trades;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">through brokers, dealers, or underwriters who may act solely as agents;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">&ldquo;at the market&rdquo; into an existing market for the Common Stock; and </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents in privately negotiated transactions; or any combination of the foregoing.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In order to comply with the securities
laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition,
in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption
from the registration or qualification requirement is available and complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Stockholder may also sell shares
of Common Stock under Rule 144 promulgated under the Securities Act, if available, rather than under this prospectus. In addition,
the Selling Stockholder may transfer the shares of Common Stock by other means not described in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Brokers, dealers, underwriters, or agents
participating in the distribution of the shares as agents may receive compensation in the form of commissions, discounts, or concessions
from the Selling Stockholder and/or purchasers of the Common Stock for whom the broker-dealers may act as agent. The Selling Stockholder
has informed us that each such broker-dealer will receive commissions from Aspire Capital which will not exceed customary brokerage
commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Stockholder and its affiliates
have agreed not to engage in any direct or indirect short selling or hedging of our Common Stock during the term of the Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Selling Stockholder is an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have advised Selling Stockholder that
while it is engaged in a distribution of the shares included in this prospectus it is required to comply with Regulation M promulgated
under the Exchange Act. With certain exceptions, Regulation M precludes the Selling Stockholder, any affiliated purchasers, and
any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce
any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete.
Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution
of that security. All of the foregoing may affect the marketability of the shares offered hereby this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt">We may suspend the sale of shares by Aspire
Capital pursuant to this prospectus for certain periods of time for certain reasons, including if the prospectus is required to
be supplemented or amended to include additional material information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.5pt">This offering will terminate on the date
that all shares offered by this prospectus have been sold by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_023"></A>DESCRIPTION OF SECURITIES TO BE REGISTERED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our authorized capital stock consists of
75,000,000 shares of Common Stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share.
Below is a description of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Holders of Common Stock are entitled to
receive ratably dividends out of funds legally available, if and when declared from time to time by our Board of Directors. We
have never paid any cash dividends on our Common Stock and our Board of Directors does not anticipate that we will pay cash dividends
in the foreseeable future. The future payment of dividends, if any, on our Common Stock is within the discretion of the Board of
Directors and will depend upon earnings, capital requirements, financial condition and other relevant factors. Holders of Common
Stock are entitled to one vote for each share held on each matter to be voted on by stockholders. There is no cumulative voting
in the election of directors. In the event of liquidation, dissolution or winding up of the affairs of us, holders of Common Stock
are to share in all assets remaining after the payment of liabilities and any preferential distributions payable to preferred stockholders,
if any. The holders of Common Stock have no preemptive or conversion rights and are not subject to further calls or assessments.
There are no redemption or sinking fund provisions applicable to the Common Stock. The rights of the holders of the Common Stock
are subject to any rights that may be fixed for holders of preferred stock, if any. All of the outstanding shares of Common Stock
are fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certificate of Incorporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under our certificate of incorporation,
as amended, our Board of Directors, without further action by our stockholders, currently has the authority to issue up to 10,000,000
shares of preferred stock and to fix the rights (including voting rights), preferences and privileges of these &ldquo;blank check&rdquo;
preferred shares. Such preferred stock may have rights, including economic rights, senior to our Common Stock. As a result, the
issuance of the preferred stock could have a material adverse effect on the price of our Common Stock and could make it more difficult
for a third party to acquire a majority of our outstanding Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Devices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our certificate of incorporation and bylaws
include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control
of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our
Board of Directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Board Composition and Filling Vacancies.</I>
In accordance with our certificate of incorporation, our Board of Directors is divided into three classes serving staggered three-year
terms, with one class being elected each year. Our certificate of incorporation also provides that directors may only be removed
from office for cause and only by the affirmative vote of holders of 75% or more of the outstanding shares of capital stock then
entitled to vote at an election of directors. Furthermore, any vacancy on our Board of Directors, however occurring, including
any vacancy resulting from an increase in the size of the board, may only be filled by the affirmative vote of a majority of our
directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal
of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition
of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Undesignated Preferred Stock.</I> Our
certificate of incorporation authorizes &ldquo;blank-check&rdquo; preferred stock, which means that our Board of Directors has
the authority to designate one or more series of preferred stock without stockholder approval. These series of preferred stock
may have superior rights, preferences and privileges over our Common Stock, including dividend rights, voting rights and liquidation
preferences. The ability of our Board of Directors to issue shares of our preferred stock without stockholder approval could deter
takeover offers and make it more difficult or costly for a third party to acquire us without the consent of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Section 203 of the Delaware General
Corporation Law.</I> In addition, our certificate of incorporation does not opt out of Section 203 of the Delaware General Corporation
Law, which protects a corporation against an unapproved takeover by prohibiting a company from engaging in any business combination
with any interested stockholder (defined as a stockholder owning more than 15% of the outstanding shares) for a period of three
years from the time such stockholder became a 15% holder unless approved by our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Stockholder Rights Agreement.</I> On
May 19, 2014, the Company adopted a stockholder rights agreement which provides that all stockholders of record on May 26, 2014
received a non-taxable distribution of one preferred stock purchase right for each share of the Company&rsquo;s common stock held
by such stockholder. Each right is attached to and trades with the associated share of common stock. The rights will become exercisable
only if one of the following occurs: (1)&nbsp;a person becomes an &ldquo;Acquiring Person&rdquo; by acquiring beneficial ownership
of 15% or more of the Company&rsquo;s common stock (or, in the case of a person who beneficially owned 15% or more of the Company&rsquo;s
common stock on the date the stockholder rights agreement was executed, by acquiring beneficial ownership of additional shares
representing 2.0% of the Company&rsquo;s common stock then outstanding (excluding compensatory arrangements)), or (2)&nbsp;a person
commences a tender offer that, if consummated, would result in such person becoming an Acquiring Person. If a person becomes an
Acquiring Person, each right will entitle the holder, other than the Acquiring Person and certain related parties, to purchase
a number of shares of the Company&rsquo;s common stock with a market value that equals twice the exercise price of the right. The
initial exercise price of each right is $15.00, so each holder (other than the Acquiring Person and certain related parties) exercising
a right would be entitled to receive $30.00 worth of the Company&rsquo;s common stock. If the Company is acquired in a merger or
similar business combination transaction at any time after a person has become an Acquiring Person, each holder of a right (other
than the Acquiring Person and certain related parties) will be entitled to purchase a similar amount of stock of the acquiring
entity.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have appointed VStock Transfer, LLC,
18 Lafayette Place, Woodmere, New York 11598 (Telephone: (212) 828-8436; Facsimile (646) 536-3179)) as our transfer agent and registrar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Common Stock is listed on the NASDAQ
Capital Market under the symbol &ldquo;ATOS&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_024"></A>DISCLOSURE OF COMMISSION POSITION ON
INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers, and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_025"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain legal matters relating to the validity
of the Common Stock offered by this prospectus have been passed upon for us by Ropes &amp; Gray, LLP, San Francisco, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_026"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The consolidated financial statements
as of December 31, 2014 and for the year then ended incorporated by reference in this Prospectus have been so included in
reliance on the report of BDO USA, LLP, an independent registered public accounting firm (the report on the consolidated
financial statements contains an explanatory paragraph regarding the Company's ability to continue as a going concern) which
is incorporated by reference in the Prospectus, given on the authority of said firm as experts in auditing and accounting.
KCCW Accountancy Corp., an independent PCAOB registered public accounting firm, has audited the Company&rsquo;s consolidated
balance sheets as of December 31, 2013 and the related consolidated statements of operations, stockholders&rsquo; equity, and
cash flows for the year then ended, which are incorporated by reference in this prospectus. The consolidated financial
statements are included in reliance on the report of KCCW Accountancy Corp., given their authority as experts in accounting
and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_027"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are required to file annual, quarterly
and special reports, proxy statements and other information with the SEC. You may read and copy any document filed by us at the
SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further
information on the public reference room. Our filings with the SEC are also available to the public at the SEC&rsquo;s Internet
web site at <I>http://www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have filed a registration statement,
of which this prospectus is a part, covering the securities offered hereby. As allowed by SEC rules, this prospectus does not include
all of the information contained in the registration statement and the included exhibits, financial statements and schedules. You
are referred to the registration statement, the included exhibits, financial statements and schedules for further information.
This prospectus is qualified in its entirety by such other information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="s_028"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The SEC allows us to &ldquo;incorporate
by reference&rdquo; information from other documents that we file with it, which means that we can disclose important information
to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus.
Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We incorporate by reference into this prospectus
and the registration statement of which this prospectus is a part the information or documents listed below that we have filed
with the SEC (Commission File No. 001-35610):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 30, 2015; and<BR>
<BR>
</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our current reports on Form 8-K filed with the SEC on January 15, 2015 and April 7, 2015, as amended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will furnish without charge to you,
on written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents.
You should direct any requests for documents to Kyle Guse, Chief Financial Officer, Atossa Genetics Inc., 2345 Eastlake Ave. E.,
Suite 201, Seattle, Washington, 98102, telephone: (800) 351-3902. Copies of the above reports may also be accessed from our web
site at <I>http://www.atossagenetics.com</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any statement contained in a document incorporated
or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced for purposes of this
prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 13. Other Expenses of Issuance
and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth the costs
and expenses, payable by the Company in connection with the registration and sale of the Common Stock being registered. All amounts
are estimates except the SEC registration fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount to be paid ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font-size: 10pt; text-align: left">SEC registration fee</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,077</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Printing expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Legal fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accounting fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Transfer Agent Fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Miscellaneous Fees</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,923</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Section 145 of the Delaware General Corporation
Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions,
suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are
currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys&rsquo; fees)
judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with
any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys&rsquo; fees) incurred
by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides
that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability
asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such,
whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have adopted provisions in our certificate
of incorporation and bylaws that limit or eliminate the personal liability of our directors to the fullest extent permitted by
the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our
stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">any breach of the director&rsquo;s duty of loyalty to us or our stockholders;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">any transaction from which the director derived an improper personal benefit.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, our bylaws provide that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">we will indemnify our directors, officers and, in the discretion of our Board of Directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 3%"><font style="font-family: Symbol">&middot;</font></td>
    <td style="width: 90%">we will advance reasonable expenses, including attorneys&rsquo; fees, to our directors and, in the discretion of our Board of Directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have entered into indemnification agreements
with each of our directors and certain of our executive officers. These agreements provide that we will indemnify each of these
directors and executive officers to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&rsquo;
fees, judgments, fines and settlement amounts, to each indemnified director, executive officer or affiliate in connection with
any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding
arising out of that person&rsquo;s services as an officer or director brought on behalf of the Company or in furtherance of our
rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We maintain general liability insurance
that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities
as directors or officers, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered
Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has sold the following securities
within the past three years which were not registered under the Securities Act of 1933:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 30, 2012, 19,757 non-qualified
stock options were granted under the 2010 Stock Option and Incentive Plan to non-employee directors for serving as directors of
the Company, at an exercise price of $6.00 per share. We claimed exemption from registration under the Securities Act for these
issuances under Rule 701 promulgated under the Securities Act, in that they were offered and sold either pursuant to written compensatory
plans or pursuant to a written contract relating to compensation, as provided by Rule 701.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On September 30, 2012, in connection with
its acquisition of substantially all of the assets of Acueity Healthcare, Inc. (&ldquo;<B><I>Acueity</I></B>&rdquo;), the Company
issued to the stockholders of Acueity 862,500 shares of Common Stock and warrants to purchase up to 325,000 shares of Common Stock
at an exercise price of $5.00 per share, subject to a six-month lock up agreement. The warrants, which have a five-year term, do
not have a cashless exercise provision. The shares and warrants were issued as consideration for the assets acquired from Acueity
to manufacture, use and sell a number of diagnostic tools, including: the Viaduct Miniscope and accessories, the Manoa Breast Biopsy
system, the Excisor Bioptome, the Acueity Medical Light Source, the Viaduct Microendoscope and accessories. We also acquired cash
in the amount of $400,000. The microendoscopes are less than 0.9 mm outside diameter and can be inserted into a milk duct. This
permits a physician to pass a microendoscope into the milk duct system of the breast and view the duct system via fiberoptic video
images. Abnormalities that are visualized can then be biopsied from inside the duct with the biopsy tools that are inserted adjacent
to the microendoscope. Based on a recent periodic review of the Acueity patent estate, these tools are covered by 15 issued patents
(13 U.S. patents, one U.K. patent and one German patent). The issuance of the shares and the warrants was exempt from registration
under Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving a public offering. The Common Stock was
valued at $5.00 per share and the warrants were valued at $2.3457 per warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On December 20, 2012, the Company issued
an option to purchase 200,000 shares of its Common Stock to Christopher Destro as an inducement grant for the employment of Mr.
Destro as the Company&rsquo;s Vice President of Sales and Marketing. The option is exercisable at $4.11 per share which was the
fair market value on the date of grant. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act,
as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January 4, 2013, the Company issued
options to purchase 500,000 shares of its Common Stock, exercisable at $4.11 per share which was the fair market value on the date
of grant, to Kyle Guse as an inducement grant for the employment of Mr. Guse as the Company&rsquo;s Chief Financial Officer, General
Counsel and Secretary. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as a transaction
by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January 13, 2013, the Company issued
a warrant to purchase 60,000 shares of Common Stock to a consultant as compensation for services to the Company. The warrant has
an exercise price of $4.25 per share which was the fair market value of the Company&rsquo;s Common Stock on the date of grant.
The warrant has a net-exercise feature and it vests monthly over one year so long as the consultant continues to provide services
to the Company. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as a transaction by
an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 24, 2013,
the Company issued 32,186 shares of Common Stock to consultants as compensation for the performance of services to the Company.
The aggregate value of shares issued was $143,550, or $4.46 per share, the fair market value of the Company&rsquo;s Common Stock
on the date of issuance. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as a transaction
by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 25, 2013 the Company issued
1,081,782 shares of Common Stock and on February 28, 2013 the Company issued 139,971 shares of Common Stock, each upon exercise
of outstanding warrants. These warrants were exercised on a &ldquo;net&rdquo; basis without additional consideration received by
the Company. These warrants were originally issued in 2011 in connection with the Company&rsquo;s private placement to accredited
investors pursuant to Rule 506 of Regulation D under the Act. This transaction was exempt from registration under Section 4(a)(2)
of the Securities Act, as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On March 27, 2013 we entered into a stock
purchase agreement with Aspire Capital Fund, LLC, and pursuant to that agreement we have sold common stock to Aspire with aggregate
gross proceeds to us of approximately $11.3 million. This transaction was exempt from registration under Section 4(a)(2) of the
Securities Act, as a transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From March through November 2013, as placement
agent fees in connection with the March 31, 2013 stock purchase agreement with Aspire Capital, we issued warrants to Dawson James
Securities, or its designee, to purchase a total of 67,000 shares of common stock at exercise prices ranging from $2.12 to $12.43
per share. These transactions were exempt from registration under Section 4(a)(2) of the Securities Act, as transactions by an
issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On June 3, 2013, the Company issued options
to purchase 250,000 shares of its Common Stock, exercisable at $4.58 per share which was the fair market value on the date of grant,
to Peter Carbonaro as an inducement grant for the employment of Mr. Carbonaro as the Company&rsquo;s Sr. Vice President of Operations.
This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as a transaction by an issuer not involving
any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 8, 2013
the Company entered into a stock purchase agreement with Aspire Capital Fund, LLC, which provides that, upon the terms and subject
to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $25 million
of shares of the Company&rsquo;s Common Stock over the 30-month term of the agreement. Under the agreement, on November 8, 2013,
Aspire Capital was issued 375,000 shares of Common Stock as a commitment fee. These transactions were exempt from registration
under Section 4(a)(2) of the Securities Act, as transactions by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 1, 2014, the Company issued options
to purchase 300,000 shares of its Common Stock, exercisable at $1.69 per share which was the fair market value on the date of grant,
to Ben Chen as an inducement grant for the employment of Mr. Chen as the Company&rsquo;s Sr. Vice President of Global Regulatory
Affairs and Quality Assurance. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as a
transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On June 2, 2014, the Company issued options
to purchase 200,000 shares of its Common Stock, exercisable at $1.41 per share which was the fair market value on the date of grant,
to John Sawyer as an inducement grant for the employment of Mr. Sawyer as the Company&rsquo;s Sr. Vice President of Global Regulatory
Affairs and Quality Assurance. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as a
transaction by an issuer not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On September 2, 2014, the Company issued
options to purchase 200,000 shares of its Common Stock, exercisable at $1.86 per share which was the fair market value on the date
of grant, to Scott Youmans as an inducement grant for the employment of Mr. Youmans as the Company&rsquo;s Sr. Vice President of
Operations. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act, as a transaction by an issuer
not involving any public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On December 23, 2013 the Company issued
500,000 shares of Common Stock to Aspire Capital with gross proceeds to the Company of $1,000,000.&nbsp; These shares were issued
upon achievement of a regulatory milestone as required by the November 8, 2013 agreement with Aspire Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From March 4, 2015 to March 31, 2015 we
sold 2,653,199 shares of Common Stock to Aspire Capital under the November 8, 2013 agreement with them, with total gross proceeds
to the Company of $4,292,349.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 16. Exhibits and Financial Statement
Schedules.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See Exhibit Index set forth on page II-6
to this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(1) To file, during any period in which
offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(i) To include any prospectus required
by Section 10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(ii) To reflect in the prospectus any facts
or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation
of Registration Fee&rdquo; table in the effective registration statement; and </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(iii) To include any material information
with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such
information in the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(2) That, for the purpose of determining
any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
<I>bona fide</I> offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(3) To remove from registration by means
of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(4) That, for the purpose of determining
liability under the Securities Act of 1933 to any purchaser: each prospectus filed pursuant to Rule 424(b) as part of a registration
statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in
reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness; <I>provided, however</I> , that no statement made in a registration statement or prospectus that is part of
the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers, and controlling persons of the registrant pursuant
to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid
by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-1 and has duly caused this Post-Effective Amendment No. 2 to the Registration Statement
on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington,
on April 23, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="2">Atossa Genetics Inc.</td></tr>
<tr style="vertical-align: top">
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 6%">By:</td>
    <TD STYLE="width: 94%; border-bottom: black 1pt solid">/s/ Steven C. Quay</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><b>Steven C. Quay, M.D., Ph.D.</b></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD><b>Chairman, Chief Executive Officer and President</b></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act of 1933, this Post-Effective Amendment No. 2 to Registration Statement on Form S-1 has been signed by the following persons
in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 30%; text-align: center"><b>Signature </b></td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 53%; text-align: center"><b>Office(s) </b></td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 15%; text-align: center"><b>Date </b></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid">/s/ Steven C. Quay</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Chairman, Chief Executive</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">April 23, 2015</td></tr>
<tr style="vertical-align: top">
    <td><b>Steven C. Quay, M.D., Ph.D. </b></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Officer and President</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">(Principal Executive Officer)</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: bottom; border-bottom: black 1pt solid">/s/ Kyle Guse</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">Chief Financial Officer, General Counsel and Secretary</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="text-align: center">April 23, 2015</td></tr>
<tr style="vertical-align: top">
    <td><b>Kyle Guse </b></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">(Principal Financial and Accounting Officer)</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center">*</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">April 23, 2015</td></tr>
<tr style="vertical-align: top">
    <td><b>Shu-Chih Chen, Ph.D. </b></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center">*</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">April 23, 2015</td></tr>
<tr style="vertical-align: top">
    <td><b>Stephen J. Galli, M.D. </b></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center">*</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">April 23, 2015</td></tr>
<tr style="vertical-align: top">
    <td><b>H. Lawrence Remmel </b></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center">*</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">April 23, 2015</td></tr>
<tr style="vertical-align: top">
    <td><b>Gregory L. Weaver </b></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid">/s/ Richard Steinhart</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Director</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">April 23, 2015</td></tr>
<tr style="vertical-align: top">
    <td><b>Richard I. Steinhart </b></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 2%; text-align: right">*By:&nbsp;&nbsp;</td>
    <TD STYLE="width: 27%; border-bottom: black 1pt solid">/s/ Kyle Guse</td>
    <TD STYLE="width: 71%">&nbsp;</TD></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>Attorney-in-fact</td>
    <TD>&nbsp;</TD></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><b>Incorporated by Reference Herein </b></td></tr>
<tr style="vertical-align: top">
    <td style="width: 9%; border-bottom: black 1pt solid"><b>Exhibit No. </b></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 51%; border-bottom: black 1pt solid; text-align: center"><b>Description </b></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 26%; border-bottom: black 1pt solid; text-align: center"><b>Form </b></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 11%; border-bottom: black 1pt solid; text-align: center"><b>Date </b></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>2.1&dagger;&dagger;</td>
    <td>&nbsp;</td>
    <td>Agreement and Plan of Reorganization, dated September 30, 2012, by and among the Company, Acueity Healthcare, Inc., and Ted Lachowicz, as Stockholder Representative</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 2.1</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">October 4, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>3.1</td>
    <td>&nbsp;</td>
    <td>Certificate of Incorporation of Atossa Genetics Inc.</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 3.2</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">June 11, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>3.2</td>
    <td>&nbsp;</td>
    <td>Bylaws of Atossa Genetics Inc.</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 3.4</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">June 11, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>3.3</td>
    <td>&nbsp;</td>
    <td>Amendment to Bylaws of Atossa Genetics Inc.</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Current Report on Form 8-K, as Exhibit 3.1</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">December 20, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>4.1</td>
    <td>&nbsp;</td>
    <td>Specimen Common Stock certificate</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 4.1</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">May 21, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>4.2</td>
    <td>&nbsp;</td>
    <td>Form of Warrant from 2011 private placement</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 4.2</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">October 4, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>4.3</td>
    <td>&nbsp;</td>
    <td>Form of Placement Agent Warrant from 2011 private placement</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 4.3</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">October 4, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>4.4</td>
    <td>&nbsp;</td>
    <td>Form of Warrant dated September 30, 2012</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 4.4</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">October 4, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>4.5</td>
    <td>&nbsp;</td>
    <td>Registration Rights Agreement, dated as of November 8, 2013, by and between the Company and Aspire Capital Fund, LLC</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Quarterly Report on Form 10-Q, as Exhibit 4.1</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">November 12, 2013</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>4.6</td>
    <td>&nbsp;</td>
    <td>Form of Warrant Agreement from January 2014 Public Offering</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Current Report on Form 8-K, as Exhibit 4.1</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">January 20, 2014</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>4.7</td>
    <td>&nbsp;</td>
    <td>Form of Warrant issued to Dawson James Securities Inc. in January 2014</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Current Report on Form 8-K, as Exhibit 4.2</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">January 20, 2014</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>5.1</td>
    <td>&nbsp;</td>
    <td>Opinion of Ropes &amp; Gray LLP</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1/A, as Exhibit 5.1</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">December 11, 2013</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.1#</td>
    <td>&nbsp;</td>
    <td>Restated and Amended Employment Agreement with Steven Quay</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.3</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">February 14, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.2#</td>
    <td>&nbsp;</td>
    <td>Restated and Amended Employment Agreement with Shu-Chih Chen</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.4</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">February 14, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.3</td>
    <td>&nbsp;</td>
    <td>Form of Indemnification Agreement</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.5</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">May 21, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.4#</td>
    <td>&nbsp;</td>
    <td>Atossa Genetics Inc. 2010 Stock Option and Incentive Plan, as amended</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.6</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">June 11, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.5#</td>
    <td>&nbsp;</td>
    <td>Form of Incentive Stock Option Agreement</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.7</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">June 11, 2012</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%">10.6#</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 51%">Form of Non-Qualified Stock Option Agreement for Employees</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 26%; text-align: center">Registration Statement on Form S-1, as Exhibit 10.8</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 11%; text-align: center">June 11, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.7#</td>
    <td>&nbsp;</td>
    <td>Form of Non-Qualified Stock Option Agreement for Non-Employee Directors</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.9</td>
    <td>&nbsp;</td>
    <td style="text-align: center">June 11, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.8</td>
    <td>&nbsp;</td>
    <td>Form of Subscription Agreement</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.10</td>
    <td>&nbsp;</td>
    <td style="text-align: center">February 14, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.9</td>
    <td>&nbsp;</td>
    <td>Sublease Agreement with CompleGen, Inc. dated September 29, 2010</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.11</td>
    <td>&nbsp;</td>
    <td style="text-align: center">February 14, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.10</td>
    <td>&nbsp;</td>
    <td>Patent Assignment Agreement by and between the Company and Ensisheim Partners, LLC</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.12</td>
    <td>&nbsp;</td>
    <td style="text-align: center">April 6, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.11#</td>
    <td>&nbsp;</td>
    <td>Form of Restricted Stock Award Agreement</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.13</td>
    <td>&nbsp;</td>
    <td style="text-align: center">June 11, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.12</td>
    <td>&nbsp;</td>
    <td>Business Consultant Agreement with Edward Sauter</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.16</td>
    <td>&nbsp;</td>
    <td style="text-align: center">February 14, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.13</td>
    <td>&nbsp;</td>
    <td>Prototype Development Proposal and Terms and Conditions, between the Company and HLB, LLC</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.17</td>
    <td>&nbsp;</td>
    <td style="text-align: center">February 14, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.14</td>
    <td>&nbsp;</td>
    <td>Office Lease with Sander Properties, LLC, dated March 4, 2011</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.20</td>
    <td>&nbsp;</td>
    <td style="text-align: center">April 6, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.15</td>
    <td>&nbsp;</td>
    <td>Office Lease with Sander Properties, LLC, dated July 8, 2011</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.21</td>
    <td>&nbsp;</td>
    <td style="text-align: center">April 6, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.16</td>
    <td>&nbsp;</td>
    <td>Office Lease with Sander Properties, LLC, dated September 20, 2011</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.22</td>
    <td>&nbsp;</td>
    <td style="text-align: center">April 6, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.17</td>
    <td>&nbsp;</td>
    <td>Sublease with Fred Hutchinson Cancer Research Center, dated December 9, 2011</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.23</td>
    <td>&nbsp;</td>
    <td style="text-align: center">April 6, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.18</td>
    <td>&nbsp;</td>
    <td>Promissory Note &mdash; Line of Credit, effective November 3, 2010, by and between the Company and Steven C. Quay</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.24</td>
    <td>&nbsp;</td>
    <td style="text-align: center">May 21, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.19&dagger;</td>
    <td>&nbsp;</td>
    <td>Term Sheet for License Agreement between the Company and Inven2 AS</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.25</td>
    <td>&nbsp;</td>
    <td style="text-align: center">June 25, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.20&dagger;</td>
    <td>&nbsp;</td>
    <td>Agreement between the Company and Accellent Inc., dated August 8, 2011</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.26</td>
    <td>&nbsp;</td>
    <td style="text-align: center">June 25, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.21&dagger;</td>
    <td>&nbsp;</td>
    <td>Supply Agreement between the Company and Biomarker LLC, dated June 24, 2011</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.27</td>
    <td>&nbsp;</td>
    <td style="text-align: center">June 18, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.22&dagger;</td>
    <td>&nbsp;</td>
    <td>Purchase Agreement between the Company and Hologic Inc., dated May 11, 2011</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.28</td>
    <td>&nbsp;</td>
    <td style="text-align: center">June 25, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.23</td>
    <td>&nbsp;</td>
    <td>Agreement between the Company and Biomarker LLC, dated June 22, 2012</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.29</td>
    <td>&nbsp;</td>
    <td style="text-align: center">June 25, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.24</td>
    <td>&nbsp;</td>
    <td>Form of Investor Lock-Up Agreement</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.30</td>
    <td>&nbsp;</td>
    <td style="text-align: center">August 30, 2012</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>10.25&dagger;</td>
    <td>&nbsp;</td>
    <td>Supply and Distribution Agreement, dated as of September 21, 2012, between the Company and Diagnostics Test Group LLC</td>
    <td>&nbsp;</td>
    <td style="text-align: center">Registration Statement on Form S-1, as Exhibit 10.31</td>
    <td>&nbsp;</td>
    <td style="text-align: center">October 4, 2012</td></tr>
</table>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.26</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement between the Company and Kyle Guse dated January 4, 2013#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 10.31</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">January 28, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.27</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Purchase Agreement, dated as of March 27, 2013, by and between the Company and Aspire Capital Fund, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual Report on Form 10-K, as Exhibit 10.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 28, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.28</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Purchase Agreement, dated as of November 8, 2013, by and between the Company and Aspire Capital Fund, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 12, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.29</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">OwnerChip Program Agreement dated September 1, 2013, by and between The National Reference Laboratory for Breast Health, Inc. and Affymetrix, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 12, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">License and Services Agreement dated June 10, 2013, between Atossa Genetics and A5 Genetics KFT</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual Report on Form 10-K, as Exhibit 10.32</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 27, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.31</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Office space Lease dated July 18, 2013 between Alexandria (ARE) and the Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual Report on Form 10-K, as Exhibit 10.33</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 27, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.32</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common Stock Purchase Agreement, dated as of November 8, 2013, by and between the Company and Aspire Capital Fund, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 12, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.33</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lab and Office space Lease Agreement dated March 24, 2014 between Alexandria (ARE) and the Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual Report on Form 10-K, as Exhibit 10.35</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 27, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.34</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offer Letter Agreement dated March 20, 2014 between the Company and Ben Chen#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Post-Effective Amendment No. 1 to Registration Statement on Form S-1, as Exhibit 10.34</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">April 28, 2014&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.35#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offer Letter Agreement with Peter Carbonaro dated May 23, 2013.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May 14, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.36#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offer Letter Agreement with Chris Destro dated November 12, 2012.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May 14, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.37</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Office Space Assignment and Assumption of Lease and Consent to Assignment dated August 8, 2014 between Legacy Group, Inc. and the Company.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">August 12, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.38</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TME Master Service Agreement dated September 1, 2014 between Targeted Medical Education (TME) and NRLBH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quarterly Report on Form 10-Q, as Exhibit 10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 12, 2014</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.39#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offer Letter Agreement with John Sawyer dated May 23, 2014.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Annual Report on Form 10-K, as Exhibit 10.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 30, 2015</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">List of Subsidiaries</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1, as Exhibit 21.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October 4, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of KCCW Accountancy Corp.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed herewith</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of BDO USA, LLP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed herewith</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of Ropes &amp; Gray LLP (included in Exhibit 5.1)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1/A, as Exhibit 5.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 11, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Powers of Attorney</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Statement on Form S-1/A,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;December 11, 2013</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%; text-align: justify">&nbsp;</td>
    <td style="width: 5%">#</td>
    <td style="width: 94%; text-align: justify">Indicates management contract or compensatory plan, contract or agreement.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 3%">&dagger;</td>
    <td style="width: 96%">Confidential treatment has been granted for portions of this exhibit. These portions have been omitted from the Registration Statement and submitted separately to the Securities and Exchange Commission.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 3%">&dagger;&dagger;</td>
    <td style="width: 96%">Schedules and exhibits omitted pursuant to Item 601 of Regulation S-K.</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>v408088_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right"></P>

<P STYLE="text-align: right"><B>Exhibit 23.1</B></P>

<P></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td rowspan="2" style="width: 50%; font-size: 10pt"><IMG SRC="ex23-1logo.jpg" ALT="">&nbsp;</td>
    <td style="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #323299">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #323299"><b><u>A</u></b><u>udit <b>&bull; T</b>ax <b>&bull;
        C</b>onsulting <b>&bull; F</b>inancial <b>A</b>dvisory</u></P></td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #323299"><i>Registered with Public Company Accounting
        Oversight Board (PCAOB)</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></td></tr>
</table>
<P></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the use in this Post-Effective Amendment
No. 2 to Form S-1 Registration Statement of Atossa Genetics Inc. of our report dated March 26, 2014 relating to the consolidated
financial statements as of and for the year ended December 31, 2013 appearing in the Prospectus, which is part of this Registration
Statement. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ KCCW Accountancy Corp.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KCCW Accountancy Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Diamond Bar, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 23, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>v408088_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: fuchsia"><FONT STYLE="color: Black"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: fuchsia"><FONT STYLE="color: Black">Consent
of Independent Registered Public Accounting Firm</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">Atossa
Genetics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">Seattle,
Washington</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">We
hereby consent to the use in the Prospectus constituting a part of this Registration Statement No. 333-192285, Post-Effective
Amendment No.2 of our report dated March 30, 2015, relating to the consolidated financial statements of Atossa Genetics, Inc.,
which is incorporated by reference in that Prospectus. Our report contains an explanatory paragraph regarding the Company&rsquo;s
ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">We
also consent to the reference to us under the caption &ldquo;Experts&rdquo; in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">/s/
BDO
USA, LLP&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">BDO
USA, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">Seattle,
Washington</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">April
23, 2015</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: fuchsia">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!C`0<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V7</4?G1N
M'J/SKQ'SI?\`GK)_WT:/.E_YZR?]]&E<]S^QG_/^'_!/;MP]1^=&X>H_.O$?
M.E_YZR?]]&K%C:WVI7`@LQ-+(>P8X'N3VHN3+)^57=33T_X)[-N'J/SH!!Z'
M-<79>%+/2+<7?B"^W8Y\OS"$'MZM5F/Q%>:JWV7PU8A84^4W,PVHOT%,X)89
M-_NW=+KLCJR0.I`^M+7+S0:?HFV\U_4'O+S&5#G@?[J#^M<_JWCV]N\QZ>OV
M2+^]U<_T%!5+`U*S_=ZKOLCT?(SC/-+7F'@J>67Q7"TDLCEE<DLQ.3BO3Z",
M7AOJT^1N^@4444'*%%97B;61H.@75]\I>-<1J>C.>`/SK*\`>)9_$>DS-?,C
M7<$NURJ[05/*G'YC\*!\KM<ZJBBB@045$]Q#'/'"\J+++G8A8!FQUP.]2T`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!X;1173^$_"_P#:C?;;
MX;;&/H#QYA']*1]I6K0HP<YE?P[X3N=;(FE)@LP>7QR_LO\`C6_?>(].\.0G
M3M"@26<?*67D!O<]6-4?$'BB7495TK0E80D^7NC&#)[+Z+6AIVCZ?X/L1J&J
MNLEX1\JCG:?11W/O0>16E*=IU^OPP7ZD%CX:N=18ZIXIN&"*-PB9L8'OZ#V%
M1:OXWCMXOL>@1+'$HVB;;@#_`'1_4U@Z[XCO-=F/FL8[8'Y(5/`]SZFLF@ZJ
M6"<[3Q'RBMD/FFDN)FEGD:21N2SG)-,HHH/12MHCH/`__(TP?[C_`,J]2KRW
MP/\`\C3!_N/_`"KU*FCYO-_X_P`@HHJ.:9+>"2:5ML<:EF)[`<F@\LX#XAFY
MUW48]$L>?LMN][./H/E'U_QKF?AKJW]G^*8X7;$5ZGE'/][JO^'XUVW@")]1
M;5/$%POSZC.5C![1+P!_GTKS3Q!8R>'?%5S##E3!,)83[$[EH.B.J<#WZJFJ
M7GV#3+JX!0/'$[H'/!(4D"DTK4$U72K6]B^[/&'QZ9'(_.L7QCX:LM8L9KV[
M:<R6EO(T2K(0H(!.<?A08):ZG`>"M6N=5^(5K>ZE<&25DDRS'`4;#P/05[$D
ML<N?+D5L==IS7@_@W2K?7/$EM8WH<PR(Y;8VT\*2.:]@T#PGIOAN2:33UE#S
M`*QDD+<#_P#70:U4KFW4-Q=V]FF^YGBA3^](X4?K6)XS\3KX9TCS4"O=S'9`
MAZ9[D^PKC_`^A?\`"6W%UK/B%GO0C^7&DI^4MC)./09&!00HZ<S/1K75+"];
M;:7MO.WI'*K']#5NO,_B!X-M-+L5UC1HOLK0N!*D1(&"<!AZ$'%:/PZ\8S:P
M'TS4I-]W$N^.4]9%[Y]Q0#AIS([NHY[B&UC,EQ+'$@_B=@H_,TYW$:,[=%!)
MKR'1+Z+QKX[#:Z^^V(=K>W9ODR/NKCZ9/N10*,;ZGJEMJ^GWC[+:^MIG_NI*
MK'\@:N5Y]XT\#V\%HNJZ!:^3>6K*YB@'^L`/8>H]J[V!S)!&[*59E!*D<@XH
M!I6NB2J+ZYI<<OE/J-HLG]TS+G^=<#\5/$5U!/%I%K(T4;1^;,5."^20%SZ<
M9K>M?`OAR_\`#L$4-K&RR1!END^^21][/]*!\MDFSK$=9$#QL&4]"IR#3JY+
MX?65[I6G7VF7L;@6MTRQ.00KJ0#E?;_&M'Q?K\GAO09+V&#SI-P10?NJ3W/M
M0*VMD;,LL<$9DFD6-!U9C@#\:AM=0L[[/V2Z@GV]?+D#8_*N`\):4_C>"XU3
MQ+++=Q;S'!#N*QKCJ0H_*N4\2Z<_@WQ:PTN9XPH6:%L\@'^$^HR#^%!2IINU
M]3W.BJ>D7W]I:1:7F,&>%9"/0D<T4&9Y7H&COK>JQVP)$8^>5AV4?X]*Z/QG
MK8MT30]-^2-%"R[/T0?UJ;PHL>B^$[O5W7,CY(^@X`_.L[P5IC:KK,FHW7S)
M`V\D_P`4AY_3K^5(^BJU%.K*K/X:>R[LUM'T^V\'Z*^IZDH-XXX7NN>B#W]:
MY26XO/%6NQK-*B23-MC#$[$'H/\`/-3>*];;6-6<(Y-K`2D0['U;\:S]*LKK
M4-1B@L<B<G<K`XV8[Y[4&U"BXP=>H_?:W['4_P#"MYMO_(1CW>GE''\ZS+_P
M/J]F"T<:7*#O$>?R-9=]_:-A?20W<MPEPI^;,IY]\YK3TCQ/KD#E8'DO$12S
MQR*7PHZG/44"MBXQYXS4EYJWXF`Z-$[)(K(Z\%6&"*2M;Q!KS:_=13&!80B;
M<#DD]SFLF@[Z;E**<U9G0>!_^1I@_P!Q_P"5>I5Y;X'_`.1I@_W'_E7J5-'S
MN;_Q_D%<A\2-4:UT!+"W)^TZC((%`Z[?XOZ#\:ZYF"*68@*.23VKS1=2@\4?
M%:VQ*K6EB&\DYX=EYR/^!']*#SH+6_8MV.@^.=-LH;2TU/3XH(EVHGE@X'UV
MUS'C?1-?MC#J6NSV]PSGR0\*XQU(S@#WKVBL/QGI\>I>%+^&0JI6,R(S'&&7
MD?RQ^-`XSU.=^%&K?:-)N--D;Y[5]Z#_`&&_P.?SKK]=_P"0!J/_`%ZR_P#H
M)KQ7P7KBZ%XDMKF5MMO)^ZF/HI[_`('!KVO5A]IT&]$!$GF6T@0J<ALJ<8H'
M4C:1X]\-?^1VLO\`KG)_Z`:]OKP7P3J4&D>*K&ZNF"0C<CL>B[E(R:]MM=8T
MZ^N3;VE[;SS!-Y2.0,0OKQ0.LO>/,?BU,[>(;.$_<2VW`>Y8Y_D*ZKX7%?\`
MA#EQU\^3/UX_^M5+XI>'Y;ZR@U2U0N]J"LJJ,GRSSG\#_.L_X3ZW%$;K29G"
MM(WG0Y/WCC#`>_`-`/6GH=KXOB$WA'5$;'_'NYY]0,C^5>1>`Y'3QIIIC)!+
ME3CT*G->H_$#48K#PA>J[`27"^3&O=BW7],UQ_PL\/RRZ@VLS(5@B4I`2/OL
M>"1[`<?C0$':#N>J$!@01D'@BO$O%?@R^\.7LEQ;QR26!?='-'UCYX#8Z8]:
M]BU<RC1KTP.R2B!RC+U!VG&*P?`?B:/Q!H4<-Q*&O[=0DRL>7'9O?/?WH)@W
M'5'#^'?B7J.FO'%J;&]M.A8_ZQ!Z@]_Q_.O7;:YBO+6*XMW#Q2J'1AW!Z5Y+
M\3]&L-+U2UFL42)[E6:2%!@9!&&`[9R?RKT7P?93:?X3TZVN05E2++*>HR2<
M?K0.HDTI(Y_XB>#[C6Q%J.G+ONH4V/%WD7.1CW&37GND^)-9\,3M%;2R1JK?
M/;3*2N?]T]/PKT=_$[:1\1[K3]0N&%E=11^27/RQ/C]`>?QQ5[QUHNGZCX=N
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M3=.2[C^W+#M,'.X;1S^E%!C):E/6F\CX;V*1\+((@WX\_P`Q2Z4?[*^'-Q<J
M?WDX=LCU)VBDOU&H?#.WD3K`J,1_NG::6S3[;\,9(H1N>)6R!ZAMW\J#U_\`
MEURO_GYJ<(!@5J^']?FT"Z>6.))4D`#JW!(]CVK.MX)+JXC@A`:21@J@G&2:
MM:MH]UHMQ'#>!0[IO&TY'YTCVJOLY_NI]>AUTGB3POJC>=J%D1-CDO%D_F.M
M1W/C;3=/M6AT.P`)'5D"+^74UP]3V%N;O4;:W'/FRJOYFBYR/+Z,5>3;2Z7T
M-O7O#<>EZ3;7YN&,UP1NAV@`$C)Q["N=KL_B+<?Z18VB]$1G(^O`_E7&4,UP
M,YSHJ4WN=!X'_P"1I@_W'_E7J5>6^!_^1I@_W'_E7J5-'C9O_'^1E:[X<LO$
M444=^9]D1)`BE*`Y]<=:Q!\+_#RD%4N@1T(N&&*["H_/B\SR_,3?_=W#/Y4'
MFJ36Q%I]C%IMA#:0&1HX5VJ9'+-CW)ZU0U[PO8>(S%_:!G(B!`6.4H#GU`ZU
ML4A.!D]*!7>YR'_"KO#O_/.Z_P"_YK9T+PS8>'5E6P,^V7&5DE+@8]`>G6M7
M>O3</SIU`W)O=G'ZC\,M$O[U[E3<6Y=MSQPL`I/?`(./PK=T;P[IF@0E-.M4
MB)&&?J[?5NM:1(`R3@49&,Y&/6@')O0",C!Y!KE=2^'.B:A<FXB2:RF)W;K9
M]HSZXZ#\*ZH$'H0?I2T"3:V.4B^'FF-<)-J-S?:DR?=%U-N4?@,5U$420QK'
M$BHBC"JHP`/84N]1_$/SI0<\B@&V]P(#`@C(/4&N2N/AKH[7?VFREO+"7.0;
M:7`'TSG%=;31(C#(=2/4&@$VMCG].\#Z78WPO9S<7]X.1-=R;R#[#I71TU65
MQE6!`XX-.H!MO<P]?\'Z5XC=9+Z%A.J[1+&VUL>GH:S(_AS8&-(;K4=3NK9#
ME8);CY/R`KK0RGHP_.G4#YFB"SLK?3[5+:SA2&%!A408`IUS;0WEO);W$:RP
MR+M=&&014M1B:(R&,2(7'\(89_*@DY!?A9H(O!,3=&('/D&3Y?SQG'XUIZUX
M)TC6K."WDA-N+<;8FM\*4'ITP17044%<TNYDZ'X8TSP]#LL+<"0C#3/R[?4_
MT%%::2QR$A'5BO4`YQ10)N^YP_@6[BO=/O-&N>58%U'JIX;\OZTGA&?^Q]:O
M=$O2`)&PF>C,/\17(6-]/IUVES:OLE3.#C/6DGO+BZNC<SS.\Y(/F$\Y'2D?
M3U,$YRFK^[+\S1U_2)O#^K[5SY9;S()/;.<?45TOBV-=:\+6>K0C+1@,V.P/
M!_(U+IU_8^,])&GZB=E]&,AAP2?[R_U%3^']/GL[>]T#4EW1L"T,@^ZZ'@X]
MP>WO3.*I7DN5U-)P>OFCS>MSP9"LWBBUW'[@9Q[D"LF]M)+"]FM9?OPN5/O[
MT6D=S)<J+)96G7YE\K.X8[C%(]BJE4I-)VNMSK?%^@:I?ZQ->16X:V2,!6#C
M.`,GCZYKC.M;\?B3Q(,0++<,QXPT`+?RK#ECDAF>.9&213AE88(-!C@XU(1]
MG-K3:QN^!_\`D:8/]Q_Y5ZE7EO@?_D:8/]Q_Y5ZE31XV;_Q_D<I\0-5N;#3;
M.VM)6@>^N5@:9>"BGK@]C4FLV7AS3--CM+Y4M5X\N?RR7#`\'>!][([GFM77
MM#M?$.F-9W>Y1D.DB'#1L.C"LK5/#>I:UIMO87VH0&.&5)?/6$B1]O3(S@?6
M@\Y-61TJ,'167.&&1D8HDC26-DD4,C#!5AD$4ZF2B0Q,(2JR8^4N,@'W'%!!
MYKX5CM)M&G@N=,GG,FHM$MRBC]T"P`^;J,5Z;7+:1X8U31=,N;.UU2W_`'\C
MR^:;8[D9NN/GQ72P1^3!'&69]BA=S=3@=305-W8VZACN+66*9%DC92&5AD&N
M`T6]F\(M:V>JL9]#U)0T,TG(@=ARC9[?Y]:]`N4EDMI$@=$D92%9UW`?AD5E
MQ^'EN/#2Z/JKI=1K&(_,5-AP!PW4X;WH!.VXGA.WA@T"+R450SR$D=_G;^E;
M59V@:4=$T.UT\R^=Y"E=^,;N2>GXUHT">YY_.EO#\2]0#Z<]W']B5_)CC#?-
MD9;!XS[UV&A111:+:BWC>*)T\Q8W.2F[YMOX9Q68OAV_C\47&M1WUMYDT0A\
MIK<D!1TYW=>*U]-M;FU@D%Y=?:9I)&<L%VJ`>B@9.``*"I.Z+4B[XV7)&X$9
M':N"UW1K'3?$7A2RM[>,0F5D<;?]8`H^]Z_C7?US^M>'KK5=;T^_CO(8A8.7
MCC:$MN)'.3N'Z4"B[,U=.TVWTN.6.U39')*9=@Z*3C./;BK=(,X&<9[XI:"3
MBO#]M"GQ(U\+&H$<<90`<*2.<>F:[6N?TSP]=6/B6^U:2\AD^V`*\2PE=H7I
M@[C704%2=V<EX\U&Y@32].MIG@&HW(BEE0X8)QD`]LYK7E\-:8]M#%%;1PM`
MZO')&N'4J<]>ISWSUS3O$&@6WB&P%M<,\;HPDBF3[T;CH14!T_6IX8K>YU&W
M$2LIDEAA*R2J#R/O87/<B@+Z&W67XEM;V]\.WMOIDA2[DC(C(.#[C/;(R*U*
MIZI9RWUB\-O<&VFRKQR@9VL""..XXZ4"6YRWA/5=.N]3AMI;!],UFU@,;PE=
MHD7C/UZ9Y_6BMJ+0I)]>@U?49(FN+>$Q1K"A5>>I))R?8=J*!RLSRBBI_L%W
M_P`^EQ_W[-'V"[_Y]+C_`+]FD?:\\>Y%'(\,BR1.R.ARK*<$&NB7QMJ#WEA)
M<%?+MS^\"#'F`\$G\*POL%W_`,^EQ_W[-'V"[_Y]+C_OV:#&K3HU?CLSK/'F
MF+((-8M<-%*H60C_`,=;^GY5SFBZS-H=X;F"**1BNTAP>GM76^$;I[S39=$U
M2WE$94B,NA`*]USZCM7-ZOX9U#2+Q@L,DT(;,<R+G/IG'0T'%AIQ2>%K/;;S
M1V%WXBUJSL#=3:(@C"!BXGS@'U&,UP&IZA)JNH2WDJ1H\F,A!@>E:TFO>));
M1K=S<%&&TGR/F(^N*QOL%W_SZ7'_`'[-!I@Z$:-W))/R;V^9L^!_^1I@_P!Q
M_P"5>I5YEX*M+B+Q-`\EO*BA'^9D('2O3:9Y6;-.OIV*][>V^G6CW-Y*(H(_
MO.>@[5,CB1%=?NL,BLGQ78W&I>&KRTLX_,GE4!5W!?X@>I^E:L.?)3<I5MHR
M#VH/-Z%8:M9&6ZB%POF6@!G3!W(,9!QZ8JS%*LT221G*.`RG'45S6K:%>7EQ
M>WUBGV?44;]Q(S`K/&452C`'H2#C/0X-=+$I6%%(P0H&*`=BO<:I:VTQADD)
ME5/,9$4LRKZD#H*L12)-$DD;!D=0RD=P>E8D-G>:9K^IWB6[74-\(V4HX#(R
MKMVG)'!Z@_6MJ'>8$,B!'VC<JG(4^E`,JW&LV-J\BS7"KY1`E;!*QD]-QZ#\
M:N@Y&1R#7+MH]_!9:[8)`LXU&622&8N`H\P8(?//R^V<\5T-A;&RT^WMBY<P
MQ+&6/\6!C-`-(@NM;T^RN'@N;E8Y(T$CA@?E4G`)/3&>,U>!R,CD&N1\0Z%J
M6I:U=3VL0\EK..(!W4+,5D+&-NX!!QFNK@8M`A:,Q,5&4)!V^W'%`-(J/K>G
MQW;VTETBS(ZQLK`C:S<J">G/:K]<TOA][SQ'J<]_$XLY9()8@'7$C1KCY@.>
M#SBNC9=R%<D9&,CM0#L4QK-@95C%POSR&)6P=I<?PANF?:KU<>F@7[>&+;07
MB"F&X4FZW#:463?N`Z[CTQZUV%`-(H?VYIWVMK8W2"991"5((PY&0N>F2*OU
MQLFAZG_;UU?"V$D'V^.X$#2+B50@7<.>&4\@'@UV.>,X_"@&D1"[@-XUH)5^
MT*@D,?<*3@'\Q4C,$1F8X51DGVKF3IVIKK]IK"0,7:22*XA+(-D)^[SGG!53
MCW-=.1D8/2@&BA#KNGSS"*.<F0E1MV,,;ONYXXS5YF"*6;H!DUD6%G<Q>)=4
MN98"MO<)"(GW*<E`0>,Y'6M:7/DOM4LVTX`[T`RM8ZM9ZD%:SF$JNF]6"D!E
MSC()'-2WM[;Z=:/<W<@B@C&6<]!6'X2TZ^TK3[2VNX959(=LA:9612"<;0/7
M//TJYXJLKC4O#5[9V<?F3S)M5=P7N.YH"RN7;;4K6[F>&&8-*BAF0@A@#T.#
MV]Z*SH-,N)_$4&I3IY"6]J8%0L"SEB"2<<8&.**`9MT444""BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
,H`****`"BBB@#__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex23-1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1logo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!``1,#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BO-/C!\
M7_AE\`_ASXE^+OQD\:Z'\._AIX,M[*Z\4^,O$<\EMHVB6^I:K8:)82WLT4<L
MBK=ZOJ>GZ?"$B=GN;R%`!NR/2Z_GY_X.7_'&H^%_^"8^O>&=*E<77Q2^-7PC
M\#26D1;S;^TM]6OO&OV=44@R#^TO"&F/L`8LZH-K#(KVN',G7$&?Y-D<JLJ,
M,US+"8&I6CR\U&E7JVK58\Z<.:G2IU)1YUR\R7-[MS*O4]E1JU=/W<)35[M7
M2T3MK9MI::GV./\`@LU_P2SSQ^V_\#=QP,G6]1)XY_Z!7^?IQ3C_`,%G/^"6
M>/\`D]_X'\`Y_P")WJ.`,]?^05P!@9/`4#/3->'?!#_@AM_P36M?@K\'[7XA
M_LF>!?$_CZW^%O@"#QSXCU#6/'L5_K_C"+PGI,?B76[V.T\6VUI'=ZMK:WM]
M<16MM;6\<UPZP00QJD:^HG_@A]_P2FVY_P"&,/AUQG(_MWXB]L`\_P#":<<9
MYYX!Z\U]%6I^%T*M>E&?'U14ZE6FY\O"ZI3Y*TJ<YP@]5"MR*4+WERU5SJZD
MC%?7G9\N#NXQD]:T)*;^)2<59V=EY-/HTWZM\,_^"I__``3Q^,OC[PK\+?A;
M^UK\(_&_Q$\<ZJNA>$_"6AZI?W.L:[K$D,MREA96[Z;"IF$,$TC"22)55'+N
MM9GC'_@K9_P3:^'OC#Q7\/O&W[8WP9\/>,_`GB;7O!OB_P`.ZAK5^FH:!XJ\
M+ZI=:'XAT2^2/3I8X[[2=7LKS3[R))9%CN8)8P[%<U_/U^SO^RY\!?"?_!RO
M)\,_V;OAGX=^'7PE_9.^!FH^--5\.Z!-K-]ILOC/4/AA9Z%?:O/-KFIZG<IJ
MT.N?'#0K,>5<^3$OAF"*.W5UN7/\E_QY\5_\)_\`'?X[>/\`S#-_PGGQL^+O
MC<S$EFF_X2[XB>)/$7FEBQ)W_P!HASECG/WFX-?I/#_A#POQ#F2HT,TX@H8.
M?#.19_;$K*WC*-?B*OF'U6A4]A3G0A2I8+`+F47SRK5XS34;I<=;,:]*FI2I
MT)2^L3H-Q<W'EIP4I23E:32;MJM]D^O^EC_P^;_X)9?]'P?`_P#\'6H__*ND
M/_!9O_@EG_T?!\#P`I8G^V]1'`ZGG22,#US7^7T4R3S^G_UZ46=S>E;&SB>X
MN[YTLK2VC4M)<7EXZ6UK;QH#AI)I9!'&IQN=AAEVEA]@_H[\+JSEGF>J*=Y-
M1RR_*E*3M[3#N"?+%ZR22MNM#F6<XB\4J5*\I1C]I_$[/J?[!GP^^('@SXJ>
M"/"WQ)^'?B'3O%W@7QOH=AXE\)>)M+:233=<T/4X5N=.U*Q>:*&5K:ZA99(F
MDB1]K`E1TKR;]HG]K7]G']D[1O#WB']I#XN>%O@_H/BO4;C1O#^M>+VU"UTO
M4]7M+9+RXTR&_MK"ZMHKX6S&XCM;B2&>X@CGDMTE2VG,7<?`WX;P_!_X*?"/
MX4VOE)!\-/AEX&\!H8$41R-X3\+Z9H4DRA3MS/+8O.S98N\C.22Q)_'3_@X\
MG\+6W_!*KXLQ:_!:W&JW7Q+^!4'@B294\ZT\2_\`"S]`NKBXL3("4N3X,MO%
M]JZQ%7:QN+R'*QRO7\SY!E6"SCBK*\FG/%++\QS>&`5:A]7^M?5*N*Q5*GB(
M1J1EAUB(TJ>'Q$N:DH-.<59Q?+[=6<J="55>SYHPYFG&6K44VGMUT\_6Y]6V
M7_!8[_@F#?WMEIVG_MJ_!B^U#4KRUT_3["RU75KF]O[^]N([6SLK*U@T5Y[N
M[N;F6*W@MX(Y)I99$C1&9E!_2BROK>_LK/4+5Y&M+ZUM[RV:6":VD:WN8DFB
M>2"YCAN8':)@S0W$,4T9)26-'5E'^?#_`,&U7[-_AWXV?M[ZO\3/%^BV>M:1
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M*<_V3R6'0'!+,$Y9E6OP'_X*Q_\`!Q)INM:5XY_9I_8+GM[_`$O5;#6?"/Q"
M_::NPXM&T^[@N=+U[1_@SI-Q!!)<&:W,MJ/B5JN(%BDDE\)Z5<>;I_BB#\N/
M^"4O_!$OXT_MZZ_H/Q(^*>F>*?@Q^R+9-)+>^/Y;2'2?%GQ06VA7RM!^$>FZ
MS!.;K3)YVAMM2^(=UI5QX7L(8KVRTA]:UZRN++3_`*[(_"G+\-PUB^)O$/,<
M7PQA5[*>6X:C+"1S&K1E2YTYX*O0JUH5L3-VP.&HREBYTU6GB:.'HM5885<P
MDZRH82,:TUI-ZJ$;:Z2ND_5-J_4_N<^"_P#P4F_89_:+\;VOPV^!7[2'@'XK
M^.;Q3+%X;\$C7]<O8+<%MUY?FVT9K73+!-KAK_49[2S5E9/.W?+7V\Y$?./Q
M[_4YXZYSP.W/)KYQ_9E_9+_9Z_8\^'5C\,/V=?ACX<^'/AF"&S.IS:59(_B/
MQ9J%I`85UKQIXGN!)K7BG7)59V>_UF\N&@5VMK*.SLUBMHOC'_@K!_P5(\!?
M\$TO@QI.NR:+;>/?CK\3SKFF_!CX:W$][;:;>7.C6ELVL>,O&5]:Q!['P5X4
MGU/2!?6D5U9ZOXDO;^WT719[4?VKK.A_F2RK#YYGM'*N$,'F>(AC*JI8&CF-
M7#+&XE>]*>(Q4L+3IX?!T8PC/$58.4HX:DG*K7J2C)G;SNE3E.NX)12<E'FL
MGVUU>VFU^Q^DGQ"^)GPZ^%'AB\\:_%#QWX3^'GA+3QB\\1^,]?TOPYH\,A22
M583J&K7%K;//(D;F*VB=[B78PCC=@17Y)^/_`/@X*_X)2>`=2O=)/[1]]XWO
MK*8PSO\`#GX4?%CQ=I<SAVC;[!XFLO!L7A;4D1ER9=-UF[C*%660JP8_PO\`
MB#QC^WY_P5Q_:/M='NKOXA?M)_%[Q#+/>:)X+L+DV/P^^'OA]9X(;F[TW1KF
M[L?`GPS\$:6\UO'J6MWK:?;W%Q/%_:>I:AJ]_$+C^A#X(_\`!J1>7WA_2]2_
M:)_:SFT+Q->6D$VJ>#/@]\/;+5;'1II(8BUG_P`)WXMUB)=5EM[AI89VB\$V
MD$IC9[:::)@X_8*WACP#P?1H1\0N+J\<VQ%.-2&5Y'%.5*+A>4IP^J8W&UX)
MWA'$8E8'#3DFZ*JQM)^:L;B\1S?5,/'DB[*<W;FLUK:3BGKVYMMS]=O"W_!Q
M'_P2A\2W<%G=?'SQ9X1EN+@6\<GB[X'?&>SLE8G"RW%_IG@K5K"SMN[7-Y=6
M\,2C=(\8!(^\_AU_P42_81^+%F-0^'W[7/P`\00,L;",?$SPSI=YF5S&L3:=
MK.H:?J`F9U:/[.;83^9B/R]Q`/\`/CXL_P"#3SX.3Z3<)X#_`&P_BII.N&*7
M[)+XQ^''@OQ/HKS>7(((KJRT._\`!]XD!?:CRI>3M$K&3R)R!&WQE^SO_P`&
M['[5?P3_`."@G[,=Y\6=,\!?%3]FOPQ\4-.^(OBSXF^"]1M9M,2W^&2-XXT+
MPUXP\%>)!8^(K%/&7B'2-*T*5(+37M&N+6XOK2?487>UCNO.K\,>#./PV-JY
M/QGG&`Q&$P6,Q<<)F5"A">+EA,-6KJA06-PN#IUZM9TXTJ=&G6E4G*I>G";3
MMI"OF,9Q5;#0<9247*#C=<S2NTI2=N[L^FNI_=0P^4D@9)&>ON!^ISVQW[TT
MD*%..<9ZC!Q[=.`"<Y'?DFC)`R<-S@\9).>O&!QQC'`7)]:_F8_X+6_\%R)/
MV1-2U3]E7]E"?1M8_:2:PM6^(GQ&NH;;6-!^!=IJL(N+/1M/TV=)-.U_XHZA
M8RVU\+.^=]'\'Z??65YJEMJFI7::=8_E7#7#>;\69OA\GR?#JIBZTFZDJDY0
MPV&H0:YZV-J<E2-/#TTXJ4XPG5E*5&AAE.I4BEW5JT,/3=2K)*"6W5OLEU?2
MUV?N=^T'^V9^RO\`LI64-Y^T1\>OAK\)7NK4WMCIGBK7[:+Q%J-H&EC6XTSP
MO9?:_$>IPR212Q1/8:7<B:6&6*'?)&ZC\S/$7_!QE_P2CT.[>TM/C=XZ\4K'
M*T3WWAOX$?&*33PT9VEHIM9\':&;F)B,QRVB7$<@PT;,A4M_'!^R+_P3O_;P
M_P""MOQ!\3_%+3=1U?Q)HY\12:9\1_VG?CKXGUC4-$C\0BW@U"YT*QU&\;4_
M$OC#7=/M+^VGG\.^$[%M/\/65W8PZC-H=O>:=%<_O]X#_P"#3SX:0Z7`WQ0_
M;*^(&K:]+%"UROP^^&/ACPSI5K<&/,L,4_B76_%U_?1(Y/V>X>/3&:,[7M%)
MP/V;%<!^%'"<HX'B[C3,,7G,*47B\%DT5".%G)1YU5C0PN8U:<.:5J2Q.,P^
M(G#E<L/3E-17FQQ>/KKVF&PT(TF[QE.T92CT=I2B]MVE8_6'P-_P7R_X)0>.
M[F&S@_:IL?"=W(R!HOB)\-/BYX$LXFE&`)M;\1>!K'P^@7`#O_:YAC.-[C.3
M^A'PP_:V_9>^-MUI5A\(OVA?@U\2-4UW[2-'T;P?\0_"VMZYJ0L["XU.[-EH
MEEJ4NK3BUTVRO+ZY9;0K!9VMS<2%(H)67^6KXJ?\&GME'IUW=?`[]LB__M>-
M1]BT/XL?"RT;3[J3!\S[3XJ\%^(+2YL5+;=IA\'7W5FR2&W^@?\`!#[_`((Y
M_M$?L7?ML?%_XN?M0^!?#MG'\/OA5_PBOP5\9^'-:T;Q/X7\6:Y\1M6\CQ-X
MG\.W4#QZWIFI:%X5\.WGA^_L]=TG1M3BM/&%W&(I[&[BGG\'.^&?">IDN:YG
MPWQIF4L=@,+[?#9/C\/26)Q=:=2E0ITJ'M\-E^(Y'*NI5<12CBG0ITI2E&::
M-:=?'^UIPKX:FH2:4IIII+=NT9/[GKZG]"_[0/[?W[&O[*GB[2_`?[1G[0G@
M'X0>+]=T*/Q1HFB>,KC4].GU7P_)>7.G#5M,D73I[6]M%O;2YLYS;3R&"XB:
M.=8V*AN0^$W_``4^_8#^/'Q`\/?"CX.?M3?##XC_`!'\5S7$'AWPAX5NM5U/
M6=3>TM9+V[:*WCTI5BM[2TAEN+J[N)(;6UB4R3S1KM)_,O\`X.6_V<M$^*/_
M``3ZG^.*:9;R>-?V9?'WA#Q)IVK"*(:@O@KXB^)M#^''C31TFPDALKB^UWPQ
MXAO8%D,0;PS%<-&7A61/R-_X-2?#'@S5/VD?VLO%.KP6L_CGPK\&/AUI_@QK
MB"":XL]!\6>,/$?_``G=Y822*9K:8RZ!X*L)IK;8QM=0EMI6$=PR2\V6\#\-
MX[PSS;C?Z[G/]I9//%83$9=!X)8*6/CB<)2PT_:RH2KQPM6./H8JO#WY1C3J
MTH5)2E'EJIBJT,=#"\E/DFE*,VG\/O75K[IQ:M:VM^]_[ET*8W@]>>.A!`'&
M>O3/Y]L5\I_M$_MQ?LD_LEZGX7TC]I/X]>`?@[JGC.RU'4?"MIXRO;JSFUVQ
MTF>"TU*YL!#9W*RI97%U!#<99&1I4^4A@:^J@K*@&<X)49&-Q!.#QG!88'0\
M\^U?YW__``<2?'[Q'^T/_P`%*=4^"WAVWN=8T/\`9W\.>$?@[X.T318KC4+O
M6_'7C&RTSQIXTFMK&!6GEU>[USQ!H_@Y+&&-Y';P=!(F1=1[?!\.>#*7&W$2
MRG%XBKA,!A\%BLPQV,PZINM2C2C2HT.5UH^P;K8JK"E-5$E*C?1<K2VQF(^J
MT>=6E)SC"*=TFF[)=.EM%?>W<_M2^$?_``4__8!^/?Q'\+_"'X-_M4_"SXC_
M`!-\:SZE:^%/!?AC4-2O]=UN;1]$U+Q'JPLK4:9&I33=`T?5=8OII'2*VL-/
MNKF:18XF(^\%.!D8QW)X&,XZ<$#(Z'/2O\QK_@AUXUMO`7_!5[]C/5[R7;8:
MQXU\>>!+H$[(YIOB'\&/B3X+T:!F="0W_"1ZYHTJQ@!Y&2),JLQ(_P!.10`I
MRW`W]L#"YY.>AQ@Y(QQGG(KJ\4."L'P+G>#R[+L3BL9A,7E5+'TJ^.]ASU*T
M\5B\+4A&.%C3A[*,J-&*=ZEY36EM3/`8J6*INI.,(R4W&T4_AM=7OW=]+Z:7
M/D_]HC]NC]D7]DW6_#WAW]I#X\^!_@YJ_B[2[S6?#%GXTGU&Q_M[3-.NDL]0
MN],N(M/N+6Z6QN988KR*.=I[4SV[3Q1QW,#2>:_"_P#X*D_\$^/C7X_\,?"O
MX3?M6_"SX@_$3QG?OIOA;P?X8O-5U/6]9O(X)[N6*TMHM)^Y;VMM/=W$\K1V
M]M:PR7-Q+'"IDK^='_@[%\<^&9W_`&*/AG%=V\_C33Y/C1X]U"T1D^U:;X6U
M:'P)X=TNXF)7>EKK.J:1JHC`=5<^'YU(8K$Z_1?_``;/?L!Z;\-?@AJ7[=?Q
M#T!/^%E?'2/6/#7P@;4[1/MWA;X+:7JYL+[7;#SP;FQO/B;XBT>>]2X\N.2Z
M\(:1H%S:S/8:_/&?5?`W#>$\-,+QMFF89O2S+,'B\+E^6T7@HX?%8VGC*]'!
M.%2I0=6EAG0P]?&8BJN>7U6A.%*3=2+26*K2QL\+3A!QII.I-IMQ33=KI\K:
MTV?76Q_5$G*C\?4="1GGGGUZ'J.**$!50#C(&.!@<>@R<#T&3@<9HK\H6R]%
MY_CI^2.Y[_Y#J_G=_P""\^E1_&#QU_P2P_9*B>3[9\??VX/#^J7\:*)5C\&?
M#BWTB+QEJ,MN,R31:79^.;.[D4`1F%)EEDC#!J_H>.`&!.6XYP.>.,9...>?
M>OY</^"N.L_ME^#?^"H?[&?[0_[/G[(WC[]IGPI^RK\%_&VI:)9V6B:T_@P_
M$GXROXP\)^)EEUG2$EG%]I'A6R\(:E''&CLE[!:)+&JXEK[7P[I.OQ10E"IA
MZ-;"Y;GF+PLL5C,+@:3Q]/)<?3R^F\3BZ]"C"=3&XRA.G[\IVI7Y+OW>7&NU
M"2=[2E34N6,I2Y75IN5HQ3;]V+VVO=G]1,914Q&`B(H5$50JHB$*BJ@`"A57
M:`!@`8'%39+#WW+QD@8RH/UXR<=,X!X.:_EA'_!87_@L:HX_X(^>(,``8,?Q
M%&1@8X%L0>3_`+0`XW-@,U34?^"OO_!9>[TZ_M+'_@D5XDTR]NK"]M[+4XK7
MX@7,FG74MM*EMJ"6T]HT-R;.=H[H6\P$4WE>7(51BPZO^(8\4N5I5.'8\LHQ
MJ2EQ5P_9W5)3FE]?;DH-NI*R?NQG[W,ES3]>H)M?OKKFG;V%71:>[?DZ::Z/
M4\(_X)M_%R"^^-O_``7D_P""GDDX_LSPI8?$#0/`E[GS&DMK&\\:>(](;3;U
M2(C!=VG@OP*YAB)=%N;`$LP7/\;D;O(JR2G,LP,DI)SF21M\O/.X%R^U@3G.
M0`#Q_7Q\!?V/OVI/@3_P;S?M2?">R^`?Q2G_`&C_`-I7X[0V8^',/AB[D^(:
M>!V\4?"CP9J%]JFC9::+3I/!O@3Q?K"S,VUK;74G5C)=(#_/A_P[(_X*&`#_
M`(PS_:"(&#G_`(0#4L<$8ZG.2N,'.#UZ$$_T]P-CLBPV9\98M9GEE*E',\HX
M<P//F6`@IY;PQD>`PV'GAU4Q--SP];,)8V="K!.E.4YQ51+WI^)BX5'3P\%"
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M!R",''3\#W!!QGC-?RB?\'6'Q=&B_L]_LQ?`^VF87'Q&^+?B?X@W\"NN3I7P
MP\,)IL321@[V7^T_B!;"/(*?N78D,`%_JX&<8;)P#VZY`.0.N/;T]:_@<_X.
MD?B<?%7[=GPD^&5K=FXT[X1?LY:+=75J2,67BSXE^./%6KZL@&\@BX\->'/`
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M._'RI^P!_P`$Q/VGO^"B_C%=*^$FB1>'?A?X?U""Q\=_&KQFM[;>!O!\$[B:
M^L]*\N.2;Q3XM,`>:U\-:)'&9+KR9-;O]&LII]0K^KOX[_\`!MW^S5#^POK7
MPF_9_LKBZ_:L\-'_`(3[P]\<_&&I3Q:S\1?&>F:=<Q77@77H(Y'T/PYX!\36
MTSZ=I.D:9IR6GA_5(=(UZ]N+Z_M]2O=0_<\ZQ7AGPOQS4S?/\5'.^)\WS6AR
MMJ&)P?"V$J4L+A,)B:U%2]AAYX2.'PR=:?UC'Q]K5Q%.A@Z="4ZWE4XXZOA5
M2HKV6'IP:FU>-2JTG+1VN[W<6EH]KMM'YG_\&^__``3!_8P_:QT/7/VB_C9X
MLMOC3XR^%_BM]$N_V6]5T1-+\*^"KQ'^U^%/&/CE/[8N;CXF:%K]C`;OP_92
MZ;HGA.*]L-3T76M.\07.FS1K_<C8V5G8V=KI^GV=K865A;PV5C8V4$5K9V=E
M:PK!;6EG;P)'!!:6T"K!!#`B1PQ*(4144K7^5I_P3\_;<^)__!.K]I_P_P#&
MKPQ9ZM/I]A<7?@SXS_#1Y39OXW\"MJB)XG\)7L%PQMK?Q)HU_8C4/#]Y/LFT
MGQ-ID$3SM8RZA!/_`*A/P8^,'P]^/OPM\!_&;X5>(;;Q3\//B3X>L?%/A36[
M4_+=:;?QY\BYCRSVFI6%PEQIVJ6$Q$]AJ5K=6,P6:"11^7>.N3\087B&CFV.
MQ^*QV0YB^7)*E7V<:.65(4*;KY="C1BL/2E.,J=>AB)T56QM%MU*]6MAZLGW
MY54I.CR0A"G5A\>GOSM]IMJ]NZUMIZGIV`$VC`"]AP0,'UZD=`!Z=Z_S)_\`
M@MG^V#J_[7G[?WQDU.&XN&^''P/UK5?@3\*=+\Y;B!=(\`:G<Z5XG\0V_EK$
MC'QQXUMM:\00)AKB'1;G0K&Y)EMV5_\`3:V@\]3V)]NAQCJ#C/;OR:_R"/BC
MYT'QG^);:B'6XB^+WCLW_GK^],\?CO53=^<'``D$BRARQ"@$<DX)]3Z.^7X6
MMG'$6;58<^+RO+<%2P;J:RHSS#$XQ8VHTFI*<J>#HX925HQI59*WOD9Q-JE2
MIK15:C<GM=4X<UGZMM>G1['^C_\`\$:/^"?'@_\`83_9%\&+=:7IEY\=_C)H
M6C_$/XT>,TL/+U.:[U^V75O#W@&VGF4WEMX?\!:1>VVC?9!(D%]K\>N>(7A2
M75?*@_74(,%Q@,0N#G'(SQGT.[..FX@X!JKI%U87NF6%YI4D,VEW=E:7.F36
MY!MY=/GM89;*6`CCR9+9XGB(X*,I'!%:-?A><YCC<[S3'YKF-65;%X_$UJU>
M552<HMU)>SHI<R4*6'A"E0A3BH^SA14(.*YE+TZ4(TJ<*<$E&,8I6[63;O97
MO=N^[O\`)1A<CG!SGDG/MVSG\>GKZ,\L9.<?-U([<'&X]3U.W.`O!7D<3TA`
MZGH`>/R/]*\QQ<8Z2M:47\,9<J3]Y1YU)J+2=U>]M$T:*RZ?J_Q_I]=#Y._;
MB_:6LOV/?V3?CO\`M(W>GQ:S-\*_`>I:WH6BW$RP0:UXKNI(-'\):7+*64BW
MO?$FHZ;%=B+,WV0S-"#*H!_R]/@[\._BC^VQ^U)X"^&UQXIN=7^+/[2?Q<M-
M*UKQ[KZ7&H3/XA\;:Q)?>)_&NKQQMOFAL(KG4M<N;:.6-!#:>6C10"W+?W^_
M\'$4>J/_`,$GOV@O[*,@">*/@;)J8C)WG2%^-G@5K\,<']UY;J90<`PB0#)(
M!_C;_P""&=YHUA_P5A_8VGUXQ+9/XN^(EG;^<$VMK6H_!3XF6'AQ%$GR>:?$
M5YI0B.0ZS;/)W3!!7]1>#"AD_`'''$^%IQEFE!9C*E6<54DJ659-+%X*AJN=
M1>,Q7UN4(R7M73IJ3O3A*'A9I^\Q>#H3;]G)QDXWLG+VO+=OKHDK/_@'^C+^
MS+^S=\+?V3/@;\/?@#\'="M]"\#_``]T.UTJU*11KJ.OZJ4677/%GB"XC`.H
M^)/$^K-<ZSK5](?WM]<ND*P6L%O!#[UA>WRX//4XQTQC.!SZ@=,>ZQ9*<\\G
MGC)R<Y..A]JDK^9<16Q&+KUL3BJ\Z]?$5:F(KU9M3G6KUJDZM:M5G)/GG4J3
ME-^ZDF^5)1C&,?<LDE%))1LDDDE96M_7WW(9`"PSZ>N/7OQ[<]B`>H%-$:9S
MC^+=DYR2`<XY.,`MTXPQ'\56**QY7T>SNK\TK/9M7E9/E;2MHF[VND-,^(_^
M"D'PE7XX?L#?M>?"](XY;SQ-\`OB.VDB12Z#7M!\/W?B3P[)M()W0ZYHVG3(
M0-RR('7YN3_%=_P;(_$]?!__``49N/!\KF.'XR_`3Q]X912X"G4/#=]X>\?6
M2,",M-]D\/7X!RKC<PW%'8'_`$&M:TJSUW2-4T348Q-I^LZ?>:5?0G&);/4;
M>2SN8CD$?O(9G3D$<\@]*_S)/^":VJ:A^S3_`,%B?V=_#NHC[%>>%?VNM>^`
M6L0*P14E\5>(_%?P/FM3YNT>5#JFMVRE7'F`1(BXE2(']Z\+(O->!/$_AR3=
M3_A)EF5"$_>2F\!BX*HEO*<<5EE&3>[M!]-?(Q]Z>*P-9=:JIR]).V^_VG=;
M-VU/]'7]I3X^>#OV7?@+\6?VA/'[N?"7PE\$:YXTU&R@EBM[K6)M.M"VE^'M
M.GGW0)JGB+5Y;'0M,,W[O^T-1MRX\M7(_A]_X(7_``#\9?\`!07_`(*9?$+]
MM/XR0Q:GH'PE\5ZW\=O&9N[::[L=;^,OQ%O=8'P]\,6DCA8!;>%S)J7B<23&
M5X[+PGH=DUN\6J236OZ5_P#!TM^UD_A+X0?!C]C3PQJ#6^K_`!9\0GXN?$X0
M28D'P[\"27-AX4T2Y`8MY'B+QW=)KCD^6P/@*.(R?9[Z=6_0#_@WC_9[TGX(
M_P#!-'X5>,/L(A\8_M%:OXG^-?BZ\>/;/<6FIZS>^'O`-JCLBR?8K7P!H'AZ
M]A@),::EJVJ3Q\73D\621GP9X39MQ+"+I9OQUBUP[ETVWST,G7M:U:M"/NU(
MRK*CCJT:L90MRT;-2HPYKJKZSF$*+UH85>UDK7YZLFG&_90=M-;ZIVM9_P`3
MO[-/A^;]G7_@K%\&_!E_([2_!7]OS0?`MU*4:,SP>"/CL_A624AT5MEY!:^8
MH9%4QSY7A@Q_U&]5U33]#TW4M8U>_M].TC1[&]U35-0NY!':V&F:=;R7=]=W
M,K?+%#;6T,DT\C8"Q(['U'^:-_P4JTK_`(41_P`%G_CCJYA%C9Z1^U?X!^+<
M!&]0ECXBU/P5X_N)P902?-NKV^D+#*['9D)*J*_KC_X.$OVR8_V;_P!@/7_`
M?A369+#XA_M;&[^$/A=[65([V'P!>Z;#??%K68&W"6*(^#;Q/"LMU"DDUI/X
MQLI[<PW*PS+])XG97B>,,S\*(X.'-7XCR"AAHU$FZ=%2J8#'8RM)6]RG@\+]
M=QE23>GLW)V;UPP-2.%IX^4VN2A5G+MHHRC%+S<G%:7O?[OY0/C5XB\>_P#!
M<'_@K:=&\!W%[I/A3XI>-+#P!\/KFZBDO[?X>?L]?#2RF_M;Q?-;6K;9)[W1
M[+Q+X_N;9+B.";Q+XJAT47ZVHAN8O]'/X=>`_"OPM\!^#?AIX&TJ#0_!G@#P
MOH7@[PMI,"JD>GZ#X=TRVTK2K;*(F^2.TM8O.E*[YI2\TO[R1B?XPO\`@U>_
M98U36_B[\<_VQ-;LUC\+^`_"1^!W@)YHG'V_QGXNO-)\3>,]2LW`$2?\(WX9
MTC1]&F56='/B^9%^:V9A_;M7ROC1F-".<Y;P=EDE3R7A#*\%@J.&@_=AF%3"
M4'6J5'%\LZ]+"QP^'J-IOGK8EM_OI7Z<LA+V4L145ZF(E*I=[J#?NI_B[::6
MZ*PBG(!/^?\`]?6BEHK\;/1(7)(P0.3MYSP"0#R#Z'T[5_!K_P`%,?\`@MI^
MWC\*?V\OVG/A1\!/C9;>$?A9\+OB))\/O#^A1^#/"^J_9;[PKH^E:9XH:2^U
M33KF[FED\51ZT)"\NU63RHU"QBO[M]=UG3O#NC:OK^L3K:Z3H.EW^M:I=D96
MWT[2K.6^O9VZ96*V@DD89&57''6O\A7XL?$'5OBW\6?BK\6->E\_6OBE\3/'
M_P`1]6E!RK:CXY\6ZOXHO5BY.(([C5I$@4'Y(5C7```K]V\!.&\LSO,^(,5F
MN78+,L+@LOPU"A1QV%I8FDL3BL8_:5HPJQ<56AA<(VI)<ZA6:3LVEY6;UYT:
M=&-.;IRJ5)7<79\L8WM?=*^O2][.Y^IO_#_'_@JE_P!'(Q?C\//`W]-''\JB
MD_X+Z_\`!5&-&=OVD8%54=R?^%>^!AA45CGC2.3@':!U;&3@$C\>JZ_X<>`=
M2^*_Q&^'7PKT8N-6^*'C[P7\.M,:-=[1WOCCQ)I7A:VF"@KGR)M465@2%*HP
M;"%B/Z6J<&<%4*=2O4X4X>]E0I3JU6\HP?NTJ,*E64KN"V5*2:;M+F7-=1C;
MPXXG$RDHK$5O?E&'\23UD[I[[V3^\_M>_;Q_;V_;L^"W['?_``2?\,?"_P"*
M5I9?M;_MB0^&;OQOXCO?#?A^<ZW-XH\/>%GTZUETZ?3Y=*TRQ_M[XA:+#=2V
MMJLMM;Z=EQ_K-V^?@!_P<U@D?\-5?L]'&1N\OPU@^_/@-3G_`(`O/4"N:_:\
MTC2/C9_P<-_\$Y?V8]%M8T^'O[*?P7TKQY)HL"L]EH>IZ%IGQ!^(EM:3*"^V
M!]*\$_"/3X8IDX-U;EGQ<1F/^K(`,">,$%NW)R2>.^><\=?U_D_.,_P_#&5<
M,4L%P[PSB<9G6`S#B3&SS;(,)F%>%/-\ZS%Y1A:%6<Z$:.&I99AJ-2C0;G"'
M-9-1M!?14Z+KU*SG6Q*]E4IT5R5913Y:5/FLEH[RYFWO=[VT7\N)^`?_``<T
M+DO^U9^SO&B@L\DB^&U1$4;G=R/`;%5506)VD`#)->M?\$!_VM_VS/VO)OVO
M=:_:C^*]M\2=$^$_C'P9\,_!AT[P_H&CZ7%XDM7\877C#4;&ZTC3[*?4+:\M
M8O#P@DN2$6U,4T<*-.S']F?VU/BP_P`"/V0/VHOC-;W$%K?_``P_9^^+WC71
MVN"?*E\0Z#X#UR]\.VIQRSW^NQZ=8PHI!>:XC0$9!K\E/^#:7X4#P%_P3,\/
M^/KJ+.K?'3XN?%3QY>7LA+7%[8^'?$DWPMT]II"Q>4-+X#U"[1G`8B^8@%2K
MMCBL[AG'A]Q+F6.X?X9P=99MP_DN5XG)N'\+E^)IXBNL7FF/_?0G5YY2P6#A
M34J=2FX-MVM)L(TG3QF'A"K7DO9UZDU.I*<9)SY*::E=)Q;O&UM+-\SU/Z!@
M,@XP!C!Z]#CUY'`Y[]J_S!O^"T_Q53XL_P#!3[]KSQ%#=I=V7A?Q_!\,;*=2
M/+^S_"[PYI7@J[B#9P#:ZQI.J0D_+_J9%8,'8/\`Z2?Q]C^.UU\*_%5A^S;=
M_#_2_C#J5L+'PIKWQ/74[GP=X:GN=RS>(;_2]'@FO-=FTV+$ECHQ>TM+J\:-
MKVZ6UBGMY?XQ_$7_``:Z_MF>+-=\0>)O$O[3OP1UKQ!XHUS6/$?B+6+_`$_Q
MK+?ZMKFOZC<:KJ^J7<OV4^9<ZC?W=Q<7!<'$KR$.-P8>KX*YMPWPYF6<YUG^
M>X'+)3P5/+<#3Q$J]6M>MBJ%3&XB<:-"KR4XT:-"-).5ZE3VSLTG)QF=.K6C
M2I4J<IISG.HXI.W+!M)WO>\E==+Z=;']17_!(_X86_PI_P"":/[$WA>***"X
MU#]GSX?^/]42&.*,C6_BII$7Q,UGS3%'%YDT>H^+)[=I74R%;=`79EWG]&"H
M5?7:OXG`QR<CJ,CKCGFOF;]C+X:?$_X*_LL_`KX-_&36?"GB+X@_"3X;^&/A
MGJWB+P6NH1:!KUAX%TV'PUX<U>*#5(X[RWU"]\-Z;I4NM1/NA.L_;Y;4K;2Q
M11_33$%6S@C!SG!!XY!SP1SR#ZU^29WB%B\XSG%SK4<5]9S;-,2\11<G1Q"K
M8[&5%6H\\8S]G6I2@X)QB_9R4.2RL=]*ZITE9Q:ITURO1I\D;II65[W7S/X7
MO^#BW_@EM_PI_P`<:C^WI\#_``\T7PN^)FN6T'Q[\.:;'&;3P#\2M6=H;7Q_
M;6<,<;VOA;Q_<(D7B!D,EOIWC29KJ26U3Q1`MOSG_!MO_P`%$]6^#WQP7]AS
MXCZY!'\(/CMJ&M:U\+;K5[KR5\$?&6'2Q?2:+8W4TIM[?2?B5INDSVHTUU1&
M\;V6E_8%2\UZ_CNO[5?VC/AL?C%\!OC%\*8=%\+>(KGXC?#CQ9X,M=)\;B5O
M"EQ>>(-&N],LI]=^SVEY=&RL+RZAU+?9PF]6>VBDLI[:Z$=U#_%]IG_!K+^V
M'I%UIVH:;^TS\$M/U32[BTO]/U33[/QS9W]AJ%G(EQ:W^GWD-NMQ:WEK/''<
MV]W;^7-%.D,D3@AFK][X5XVX;XIX`S+@_C[-L+@*^$A#"95F&+52IB*M*G0Y
M\OKQE2PU>I]9R:K&&&<IS5/'82O3I\Z=.4GY=?#5L/BH8G#0E.,W^]IQMHG9
M-*^EFM=-5T9_=9N(0#H1C.?IR3WZ\G';@9K_`#0_^"Y?[&^M_LF?M^?%JZ73
MV3X7_M&:WKGQP^%NHH8?(F@\7ZA]N\?>&MBMF"3PEXXU'4[.&UVB6/P]>^'9
MU#/<*S_WR_L1>$OVU?A]\-E\"_MI?$#X5_%WQ5X>CTNQ\,?%+X>6NMZ1KOB3
M2[>U%M+%X]TC5+1+.XU^,P13R>(M,N%_M=YYI;ZS6Z#7,VM^V/\`L*_LS_MV
M^`M-^'W[1_@&+Q98:!J%WJGA/Q!IUY+HGB_P;J6HVZVVH7OAGQ#9JUU8#4((
MH4U&RD2XTS4S;6AU"RG:V@:+\]X`XNI>'/%>+J8C$4LVR?%4*N7X_%91-5Z>
M(HQFL3A<=@OK4,+[186M2C[:CB84*\J=7$X?W:])WZ\9AEC:"BKTJB]^'-:Z
MDX\LH]='L]WU5NGX\?\`!$G_`(+(_!CXX_`GX<?LQ_M`>/M"^'W[1_PJ\.6'
M@G2KKQ;=IH?A_P"+/A'PY'!I/A?6=$U[4)$TH>+[;14T[3?$7AVZOH;^^OK2
M?7-'AN+&YNK;2OZ18KA9XDFA*312HLD4L+"2*5)%#))'(N4>-E.X.K$,"-I-
M?Q7?M%_\&K7CJTU>_P!8_92_:,T'6-"DN7FT[P;\:-(OM)U[2D8M)]GA\:^&
M%NK34&@P@@N9]`L+@X5I'22-I*^7H/\`@BC_`,%U/"D:^&?#'CW68_#?EQVB
M_P!A_M:W>DZ-#:1DQ(D&F3>)+6Z@@2,EQ%#:H-I"B(,NT?59UPIX;<2XRMG/
M#OB#E>14\?5GBZ^59UA:^'>'KXB7MZ\*$:OL*E&,9U:C6&G+$4HU).E1Q$H\
MG+STL1C:,?95\'.K**48RHM-OE5ES?9NTE=I[=-S^Z#XJ_'?X._`WP[J?BWX
MP?$WP/\`#?P]H]E-J&H:AXM\1Z;I)BM;>,RR-#:7$XO;V5D5A#;6-M<W-Q)L
MAMX99I$0^9?LE_MA?!G]MGX=Z]\6O@'J.LZ]\-=(\>^(?A_IWBO5M$OO#]OX
MIU#PM#IK:SJFA:?JD<&JG1$N-1%G:76HV5C<74MK<L+5%0$_QS>#/^#:#]O_
M`.+6J0:E^T+^T%\/?",+N6N;G5_%'B_XQ>)(@^6E,$#75GIX9P`N1KH`=]Q5
MEW`_UG_\$U?V.Y/V$/V.OAA^S3J7B#2?%OB'P;=^-]1\4>+=%LKG2].\2ZSX
MJ\;Z_P"(%U&#3[N::XM!%I%_I6EB"2:5H5T\1B1P,GX[B;A_@G(\H4<KXP7%
M/$%3&T(.&!PL\+EN%P+A7=:<U4I3G6K59>SIPDL94C"TG[./,FNFA6Q-:=YX
M5X>DHN_.[U'+3E5D[6WN[>AZE^V?^SEIW[6?[*WQW_9UU"\33_\`A:_P[USP
MYI6IRC]UI/B41+J/A/5IMJ.QM],\36.E7MR$4R/;0S1H0S@C_+)L)?C1^QU^
MT-I=Y>Z7>_#[X\_LY_$_2]4?2=5A;SM`\<^`]8AO(;>[2.2/[9I=Q<6D0BFM
M91#JNDW<=W:W)M;N&:3_`%TW/RD`@'@?3)QT_IWZ5^5?[=__``1^_8V_;_U&
M7QM\3_"^J>#OC`-"BT2T^+WPZN[?1?$\]O9O(^E1^);22VN-)\6QZ69I(K;^
MV;=[R*RD>PCU"&U`C7VO"SQ%P7!L\RR?/*%7%</YRXSK*C1C7J86O*@\)6G[
M&52"KX;$81JEB:45.I!0C5IJ[?-ECL'+$\E2DU[:EK&^EU>^[T3OY?YGH_\`
MP3Z_X*2?`/\`X*!?!SP_X]\`^(M'T#XAI!#IWQ$^#^K:O9V_C#P=XMAMH)-2
ML[;3KJ6&\UKP[<RR_:/#_B*SADL]2LI565K;4+:^L;;]"R[`9V?4<_[/.<=.
M6R2!C&3Q7\)?Q:_X-B?VT?ACXKFUC]F3XZ^`OB!I,!:32-2OM9UKX1?$&U'F
M%5AGDL9;K26G2(AI;RVURVCD9W"VB*[(>"3_`((O_P#!>#4@GAS4?B'XB@\/
MQL\23W?[7=Y<Z6(F.PD6EMXEFU`Q2@ME'M@0,C:Q(6NS&\!>'V85ZF+R'Q.R
M++\OK3=2G@LVIU(XS!PJ2YXT&ISH5)1I)N*E6I>UY>3GG*2<Y1'%XN$5"K@:
M\IQ5G.#CRR:W:W24OZ\O[)OVD_\`@H7^QK^R1HE[K7QX^/\`X`\)2V<3LGAJ
MQU0>*?&M],L<LB6ECX/\,)JVOR33&(Q1R364-HDKQ"XN85E1J^C?A'\2='^,
M?PN^'OQ9\/6&KZ9X?^)7@[P]XYT&QU^T2PUJ#1/%&EVVLZ2-4LDEG6SO9-/O
M+>6>U$TI@=S$79E)K^*'P]_P:M?M1^*/#^KZO\2/VI/A1H/C>ZLIY;72;/0?
M&'C>*[U&<Y,&L^*;Z_T:Y12C2+-<6VG7F+DK(K2I&9*_M_\`"/AO1?!7A7PU
MX-\.VXLO#_A+0-'\,:'9[@WV31]`T^WTG3+;<`H;[/96D$.0J@[,@`<5\=Q=
ME/!F38;+J'#?$E;B3,*F(Q?]IXE4HX;!4*%.C15"&'I>R@ZGM,1*NE5=:JW"
MDM%S)OIP]3$5)5'6HQHP7+[./-S3=]W+5I+Y;F_)PAS[?AR.3[#J3T`Y/%?Y
MCO\`P4DT>\_9F_X+(_M`>(+)C83>&/VOO#O[0VDW3,543^+_`!)X6^.?VY65
M&Q''K.NWA;"E_P!Q-\W`9?\`3AEVE&!P0<<'']X8S[9'.0>AR#TK^5S_`(*F
M?\$'_CY^WC^V-XR_:0^'?Q1^$'P_\-^(O"G@+P['I/B2V\4W>N7E[X2T*/3K
MG6=2:QLC9P2SD1VT$,!)2UL;625C.[!/H_!WB+*.'^(,V6>8^AEV69IP_B<#
M6Q6(]JX*LL1"6%A!4:5>;G/ZUBKWI2CRQ5S',J-6M1I^QCS5*=95$O1>MM+=
M>Y_.I^U)XW\4?\%?O^"M6HV'@&\NKC0/C5\7_"_P<^%5R8)8XO#7P4\*&#0A
MXH-G.7DM5&@:=XB^)NJQ.2#JFI7L6Q8XTB7_`$G?`7@7PW\,O`W@WX<^"].C
MTGPEX"\,Z%X.\,Z9&!ML-!\.:9;:/I5J2JQAVBL[6!9)2H:67S)6&YSC^<O_
M`()$?\$,O'_[`/[3&O?M`_&OQQ\,_B;=6GPTUCPI\-O^$2A\06]WX2\2>(=4
MTJ'6]:>WU:WAMIWO?"T&HZ+!<I*)+2WOKN)+>;[6)8?Z8SPN-P&.N.,YP&SC
M/.<],GTQQC/Q6XHR;-L1P]D/#&)AB^'>&LHP]#"U*7.H5<95IJG5G-584:CE
M2H8:CAW.I"$Y5ZU>I:'MJO,\OHU:<:M>O!1KUJC<EVC=M7M?:^R[>A_G<?\`
M!S'X!E\(_P#!3/7-?C5X#\4_V>OA'XYMYXR?FN=/?Q=\,I'B8+D7$/\`PKZ$
MLH)*JT4N"THQ\N_\%3OVV-:_X*!?'_X,1>$GN-=\-_#7X)?![X3^!-(M8KE3
MJOQ&\5>%O"^J_$][:U<LTE[?_$N^;P;%/LC>^MO"FF,ID@2)C_5K_P`%E/\`
M@C=\9O\`@I'\=OA1\5/A?\1/AC\/K'X??"63X>ZHWC&/Q'=:UK5X_C#6_$EJ
M(XM)MIK.WT[2H=5E^ROO%U<76IWPE40PVA;Y)_X)^_\`!N1\2_V:_P!KGX/?
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MS^28_P"#:[_@EX`!_P`(9\8>`!G_`(7)XE!./7$8S]3SSZ8`_=?"7Q$X9X&R
MC-,+FU+,IXW,,RCBKX'!QKTEAJ6$IX>C3<YXW#V<:D\74M[*7\2.J;T\G,,%
M7Q=2G*FXJ,(<OO/K>^VKLE^)_G69_P!IA]>/_9J_4;_@BW\+S\6?^"G_`.R)
MH#VXNK/PY\0KKXF:A$4\R)+7X9>&M5\:132XW*L<>H:;IK*S``2/'R#T_L-_
MXAKO^"7G_0F?&'_P\OB;_P"-U]-_LB_\$9?V&_V(_C):_'CX%>%/'=E\0['P
MQX@\)6-[XJ^(.L^*M.L]*\3_`&%=6>WTR_5;>._EAL1;17N3-%;W=]"I*73@
M?>\1>.7"F/R#/,!EM'.XYACLIQ^"P<JV!HTJ"Q&*P]2C3=>I]<KSC2C*I*4W
M3I\[7NJ4=US8?*\13K4ISE2Y(5(RE;5V5]KKS_7H?C+^R#\;?@UK7_!P+_P4
M;_:(^,GQ6^'G@'0_AEX.U+X+^`]0\?>+M!\,VE_J>G:G\/OA_/\`V%/K5_9I
M<W.FZ3\-]<AO(;7S)(8-8EEF0"5F;^C[_ANO]BKC_C+/]G1?E("CXQ>`P,=,
M<ZWE<9P>-P.>_(_./QS_`,&['_!-7XC>-/&'C_Q;X3^+NI>)O'?BWQ+XV\27
MC?%[Q"D=YXA\6:Q?:[K-U'!Y1CMTEU#4+AX88@J00".V3]Q&$KE1_P`&TG_!
M+(`#_A`_BUQ_U6'Q+SUZ_N^O/7OU.223^2YYCO#?/Z^`Q&(S?C+"O`9'D>34
ML/A^'\FJ4*=/*<##"OV<ZF<4ZLHU*CQ%7FJ0C.3J)M)[]].&-I1G%0P\N:M.
MI=U:L6U*3:;459-*RMY:ZW,K_@MW^VK^S1XD_P""8/[4'A'X9?M#?!_QQXQ\
M8:-X*\-:?X=\&?$CPKK_`(@OK*]^(OA.ZUQ;?2=)U2ZOKFW_`+!L=32^,<#)
M':/,)64,N?TH_P"":/PH3X(?L`?L?_#)K5;2\\/_``"^'5YK42KY9/B3Q3H=
MOXN\47+Q`DI->>(M>U.[N`3N6:>3<`PQ7YX1?\&U/_!+2&6.5/`GQ:#1R)(`
M?C#XEVL8W5PK@(-R$J`Z9PZY5LJ2#^\6CZ/8Z%I>FZ+ID0MM,TC3[+2M.M5R
M5M]/TZUBL[2W!)+,(K>&.,,Q+$*,\U\_Q#F7#E/AO`<.<,8G-\73CG6*SK,<
M3G&7X/`RG6EEV&R[!TZ-+"XS%QJ0H0CBZG[V<6O;)*]V;T85O;3JUHTHMTH0
MC[.=23NI-R34DDEK>^[M]_Y\_&_Q3\:/B]^UI%^RE\*_C#K7[/.C^"/V>='_
M`&A/%/C_`,,^%_"WBKQ3XRU3QO\`$3Q9\.?"OA'3K7QE8ZAI-CX<\,+X*US7
M_%D]M;R7]_<ZWX5T\2V%J9FN?G7X\_M\?'#]CR/]FWX1^.;3X,?'SXH?$3PE
M\;]7\7_%>RUGQI\/_!%P_P`&O%W@WP[;QV_AKP7X&^*.H6OBK6;+QG9Q^)].
M6.VTC1/$>FZM8P2BW>VMF_03X]_LF?#K]H'6?"_BS6/$?Q1^&_C[PCINK^'M
M+^(WP5^(.L_#+QS-X1\0207.M>"M5US1=QU7PK?:C9:=K"Z;>V\KZ=K.G6VI
MZ3<V%V;B2?Q'Q%_P3'_9LU/1O@SHWA+4_C5\'_\`A1/AWX@^&/!&M?!OXS^-
MO`GBBYTWXJZ]H/BGXA2^+/$]G?W.N>+-1\6>)?#MAKNL:AK-]<7%WJ;7%S(Q
M9HO)YLMQ_#D:>7T\SPWM<+0PTZ=;`QRNE*;QRP..IK'ULUH8G#8^O1K8ZO@Z
M\L#3DU2AAO9QJ1IQA3JW4C5?-[)\LFU[W-?W>JLUI=?YZO;XL^.'_!67XK_`
M7QYK'PU^('PD_9W\(^)?!OP:\`_%OQA>>*_C[XZTSPW.OQ"U/XB1:7I'A;5;
M'X)ZJUTMGI/@JPNM3O-?M="\C4?$,-C#!<16LEVWM7_#</[7^N>)?V7](\-?
MLG?#72;+]K;P1J'C;X=Z=\1_C9XE\,^,/"L/AGX7>&/B'XKT?XAZ):?"W4XM
M)U6RFUNZTBP@L;N\%PUC%<7BV$MPT,7UE\/_`-AKX'^!=+^+.DZC)\0/BI%\
M<OA?X8^#OQ5O?C/X]USXE:OXR\`^$9_B7+H^D:KJ^NR/J$K)!\6?%VGS70G$
M[Z>VDVZ-$-*MF'<Z!^R]\-?#]U^SIJ"W7C'6M5_9;\->)?"?PKU?Q'XIOM9U
M2/2?%?A.Q\$ZJ/%%]<*)_%%Y_P`([IMG:P7VI,UTLT/VR:2>Z=Y6*V9\+1HP
MAALAI2Q-*&(C/$5WCY4<55J97BO85X8=9G&>%C1S9X51I5)UYQPB<G.JU6A)
M*%;FYG4M&\6HJUHVJQE+6VMXJ3Z:RMOJ?D;J?_!8WQ[I_@C]G'7(O@K\.(M>
M^./A+]ICQ=JW_"1?$'QW8^'?#MO^S[^T%)\$H-+TZ;PG\,?'6N:K?>([=[77
M9)KO2--LK%XKNS:X=WM(Y/2/CK_P4\^,_P"SW\1/B!\,/'/P)^&B^,_`?P-_
M9.^)&HVNG_$[Q9?>'X/%G[2G[2?BSX$W6C2:]IWP\O=8N_#WA33O#UCXCBO=
M.\'W.IZK?75QI::=%&@NF_0#X+?L3_`KX!:W\/O$'P[TWQ'::E\,?`7QD^&W
MA1]5\27NJQ0>%OCO\7](^./Q`M[V&X4+?7=SX]T2RN-+O)<2Z9I8FTN'=#*S
M5S'QN_X)_P#P$^/?C_QM\4O%UQ\2="^('COP9\&?`NI^*_`'Q"UOP7K&EZ1\
M!/BAJOQ@^&]WX:O-)*S:!K>F>-M9O;R\U:P=+F_M##92E8HE-=BS/@F6/L\@
MG#+8PQ4O:2EBZN*J5:V;T\1AZ+IPS"#I8?"Y9">'YH5)5:LZJYKSA&JLU3Q*
MI).JW.]/:44K*,%/5PEJVI6T^>MSYC?]O3]I/_A5_P`"/%UG^S_\'-9\5_M,
M_'^S^#'PATK3OC7XULO#%WIB^!?B%XLUSQ/XIUGQ%\(-$\0:'<V%[\.]5TJT
MTC_A%;MK^.6*^BN%BEC$GV!^R[^T9XA^.$GQB\&_$?X;#X5?&/\`9^^(6G_#
MGXH^$+#Q+;^-?"S7^O>"/"_Q&\,:_P"#_%L.GZ2^L:%X@\(>+M'OHUO=*TO5
M-.NS<V.H6<<D*%_'M4_X)D_!K7_"EEX6\1_&/]KKQ))HGQ'\.?%7PIXM\0?M
M+_$/5O'?@?QCX8\-^+?"=G>>"?%MW=R:KX8MKW1?&NMV^LVFERPQZJ_V&2Z+
MFRA`^HO@+^SA\,/V;O#.L^&_AK9:X9O%7B.[\8^./%OC#Q-KOC?Q[X^\7WUK
M9V%SXE\:>,?$M]?ZUKNJ-I^G6&G0-/<+:V.GV5K8Z?:VMK$(CY.95^'*F7U:
M>"PULPE6DZ=:GA<9A80I?6:,X)_6,SQE-T8X)XC#NDL.\1+%J.)6(A0FJ4=:
M:K*7OMV3_G4OLM?9IP:]ZSZZ:'X9^.?VJOVQ_$'B_P#;7M_AQ\3_`-JNY\7_
M``E_:$^,7PS^!W@/X1?L>^%OBS\)KT^$-$\-7G@?PUXG\?3Z4EPEQ?ZUK#6/
MBE[W6K>XTC2KF"_)B'D&;]!X/V[_`!GHG[(WQ,^/_CGX3Z3;>/?@[\<_#O[/
MWC+P-IGBR1](NO%<OQ;^&?P@\4:Q8ZU_9,\EK9Z=K'CC4]4L;,VMWYUMI%O;
M-?[+UKN/[B^%OP4\#?!V3XF2^"+?4;5_BU\5_%?QG\9?;]1GU$7/CGQG;:-:
M:Y=6(G_X\-.EBT+3_L^FP_N+9EF:,_OFKY@\2?\`!.'X!>*O'/B3Q9JNO_&D
M>%_&GQ7TWXX>,O@I9_%GQ):?!#Q3\4=*UC0?$D'BG5_`D;?.\WBCPQX?\37F
ME6NJVNB7>MZ5;WL^FN7N$G[Z^;<-Y@X8;$Y53PF%PKRRK3Q&'PSEB,9'#83"
M8?,L#6IX=X&-*ECW2JU(3JU<7R8A_67B*4:CHI<E6/O1G>4E)--V46W+E:;O
M=JZ;T6FEKGQMXR_X*U>)?"'[2OCOX,/\%O"UUX,^'W[5/P^_9LU?7SXS\<Q>
M+KBU\=:Q\-=$?Q]!:I\+[CX>6.GZ%+\1XM2O]-UKXA::_P#9>@ZA*;F.>ZL8
MI?T0^#G[1EW\6/AA\<?'X\)0Z%<_"#XS?M._"2UTPZK/J$.NC]GOX@>+O`UM
MKL]T;&U>Q'B=O#":C-8+'.=,:[:VCN;IH#(WENM?\$UO@#K_`,4_&GQ0U#Q7
M\?UB^(WQ1TGXQ>._A;8?'+QQI?P6\6>.=&D\+S6E_KOPST^]MM"O[1Y_!GAF
M:[L)U:WNWTFV$X=-Z,:1_P`$WO@SX?\`B-XI^(?A_P")W[3VA1^-?BCX\^+W
MB;X=:1^T#XWL/A'JWBWXF^(=4\4>.$NOAS!.GA^31?$.L:S?W%_I+0&"5)O*
M9B@(,8JKP=B*.'A2HXC!UJ=#+YU:U/!8NHJV(H5\OJXZE6C/,WS3Q<*6/HK$
MTE2H0A7IOZM=.TQ6)BYN4E/F<K7<5:[JV=^7[/-!]]_._P`R_`;_`(*._M!?
MM2_#GX-ZG\`/V<?`?B?XE^(?V2O@U^U7\8M"\7?%/4O`WA/PS:_'"7Q5;^!_
MAWX#UE?">NWWB'Q3JDG@7Q9>RZAJ]IHNAZ38VVFB^OGNM1$,/ZX^%=:O]>\*
M>&]?UK1)_"6IZSX?TG5M5\-WVH:;J5UX<OK_`$^"\OM%O=5TJ>?2;^72II9+
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M]MJ7Q=\&?#O7_"\OC/P5XS\<^!KSPSIVA7`U[119/J'ASPMXIU?7-$N=5MH&
MBO'@O/)]WO\`]B']FRY\/_`[PWIGPZTOPM9?LZZ_X/U_X67?A.*#1-8TG_A#
M?#EUX-M]#U75X('O?$GAKQ#X.U#4_"WC/1->DO[7Q5HNI7MOJWG22+,GFWP\
M_P"";G[._P`-/%/@W6M"U3XSW_A'X9:[<>)/A7\%_$7QD\;:W\%/AGJ\L-U;
M6LGA+P!<Z@+5+'1K6^N[70-'UJ\UK1M"MIC%I=A;+'#Y?J8S&\)5_;U,'E^(
MP<YT*5"%/%8=XJ*6#H8O"4ZM">!Q^`A1Q./A'+\77K8BEBO95_K4*D:J;]I*
M5>UG.ZWM=1LV[ZWC*Z6JT[IK8YWX;?M3?M,ZEIGAWXN_%_\`9O\``_@;]F[Q
M9X"\1?$R+QCX5^,R>+?B!\/O"6F>#=1^(.@:AX\\%7GA;1+#4I?$/A;372>S
M\#ZSKE]HFM7MI8SPW5A%>ZE!SWPH_;*_:2\7V?P(^*OC_P#9F\'>!OV=?VC=
M4\(Z?X-US3?C%_PDOQ6\&6GQ2TXW?PBUCX@>$E\*6/AY[7Q=J$^B:1K-IX9\
M4:M=^%KCQ%8S7*ZA;6>I-!ZI\-?^">/P&^&7C#PQXILM;^,WB_2OA^NOI\,/
MAM\1?B_XP\9_"OX91^(["_T74(O"'@G4[S[`((?#NJZIX:TJV\02:];Z-H&H
MW.FZ7%:1&(QU_A?_`,$Y_@!\(_%W@3Q#X6UGXSWGA?X4:M=Z[\)/@YXG^,/C
M/Q+\&/A?K%QI]]I-K>^#_`FJ7TT$/]A:;JFIV?ABTU:]U?3_``S'>R/HEI8S
M0VDMOE4Q'"W^U<N%C.4H/V-LNQ]*G[-TLS5.A3C//J[H8ZCB*F65JF8U?;X:
MM"E7IPP49.52NTJR^UZ>_&7;?]S"ZWLKWO\`AS?@+]NJY\;?"#_@GG\47^',
M.G/^W3XI\,>'+O1E\1S7"_#E?$7P:^(_Q8^U6]X-)B/B,VTG@-=%\J2+2Q*F
MJ-?[@MMY$OR[^S__`,%:M?\`VK+_`.$O@+X+?`?3K/XS?$3P3^T7XHUCPA\4
M/'6I^%="T!_@9XV^#_AG0M8TS7]-\(:W<>)/A_\`%+2?B%XLO_#GBNRTJ(0Z
MY\/M9\.36,UY::E-9?7/PE_X)L_L^?!OQA\+?$_AO7/C1K.B?`K4]>UCX&_"
M_P`:?%GQ)XH^%7PAU'Q!H6N^%Y[GP5X1OF`B;3?#7B;7=#T%=:O]971+#49A
MIZP7"07$7=_!_P#81_9T^!NL_!;Q'\/_``SJEEXB^`GP_P#BA\+_`(?Z[?ZY
M>:AJB>"/BYXTL_'_`(LT37[F7:=?@B\469O]`:^5GT(7NIQV)5=1NS*5,1PC
M16,]C@,7C:CIXNIE\ZL\5AJ=*O.MF53!4<51EBI_6*-*A/+,/B)JI3G*="56
M$IP=>%9VJMQ?-R6TE:S=N5)M.RLV[OKO;L?"4?\`P5"^,GAK]E?7OVGOB7^S
MU\-M+M=<\?>(_@M\!_AUX3^-]SJWBWXL?'7PO\8/&WPBO_!UQ+KO@;PYHWA_
M1G?X>>+?%R:[_:&I-%X;TFXO+O3X5AGDCZ+Q-_P6)^"VA>*-`MH_#%_+\-OB
M%^QAX5_:H^%OQ=O-42T\$ZAXM\8CXKGPW\#O'6HK936O@?Q+XF/PLU33?#6I
MWEU<6^J^([34O#D5J=473(+_`.MK;_@GM^RZ;3X7Z1XA\#2>//#'P>UGXX>)
MO`_@SX@WO_"7>#K/Q5^T'XYU3Q_\0?%.I>'-4@DTW6?$$>K:[KEAX5O]3BN#
MX4T36=2L-'C@>ZDN#3M_^"<G[)46B_%'PI<?#:+4?!'Q>^&`^#OBOP'J%]-/
MX.M?A[#\2/B1\5].T+PSHB+%#X;CT/QG\5/%-_X?FTQXI=#A71K;36MUT>S9
M.KZ[P+4G6=?)\Q5\3B)TU@Y_5J"P=6>"IX:C"G6Q^+K+%86C1Q6)J5:U:=#$
M5\1+#.,*,HU:$<N)3C:K!KD2=X^]S<LD[.R5FVK::))][_/MO^VS^U/J?Q._
M9G\':'^S=\)+WPU^U#\,+SXP>"]9F^./B*+7K#PCX7\$?#/QAXSL=6T'_A63
MVT?B2!OB%'I>@6<.K2:=J\]CYUUJ5I%+*8\[]DC_`(*2^-_V@?C?H/PF^)OP
M;\,?!&Z\:Z3X\U/PSX4\2>,_%VD_%[0K[P/=R23>%_$7@WQG\._">D>)=>71
MD_M'6O\`A7?B+Q';:"(KF>Y$VE!;]_N^U_9;^$UKJ_P,UN.QULWW[._PP\4?
M"#X;,=>OT6U\$^,/#OA+PMK=KJS0/%/J>HRZ1X+T2.WU0SP7=I<)<W4#I-<,
MR^3_``W_`."?_P`%?AM\4/`GQ63Q1\</'VL_"6#Q/;_!O0OBO\8_&/Q%\*?"
M1?&.E/X?UZ7P1I?B*[N;J&YN?#;OX<M[O7=1URYL-%9[.QE@#N[<SQO"U7!X
MRE/*E0Q$\%7AAJ]*CBY5HXOZQFD\,XR6:2PW(\.\EI8F6(H-I4L8Z$;R2F^2
MLI1:J-QYDY)VV]E2BULG\49O375=-OMU?O`<9QD@?3M_/T]ABI::%Q[_`.?_
E`-?YTZOD()I6:L[MNSNKMW=F_>M=NRE=I:;)'0W<****H1__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
